ABSTRACT Neuroendocrinology of bone is a new area of research based on the evidence that pituitary hormones may directly modulate bone remodeling and metabolism. Skeletal fragility associated with high risk of fractures is a common complication of several pituitary diseases such as hypopituitarism, Cushing disease, acromegaly, and hyperprolactinemia. As in other forms of secondary osteoporosis, pituitary diseases generally affect bone quality more than bone quantity, and fractures may occur even in the presence of normal or lownormal bone mineral density as measured by dual-energy X-ray absorptiometry, making difficult the prediction of fractures in these clinical settings. Treatment of pituitary hormone excess and deficiency generally improves skeletal health, although some patients remain at high risk of fractures, and treatment with bone-active drugs may become mandatory. The aim of this review is to discuss the physiological, pathophysiological, and clinical insights of bone involvement in pituitary diseases. (Endocrine Reviews 39: 440 -488, 2018) 
P
ituitary hormones are involved in the regulation of skeletal physiology, and bone loss commonly occurs in pituitary disorders (). The traditional paradigm is that pituitary-derived hormones exert their biological effects on bone by peripheral mediators produced by target glands under their stimulation. However, there has been growing evidence to suggest that pituitary hormones may bypass traditional endocrine organs to exert remarkable direct effects on the skeleton.
Pathophysiological and clinical relevance of these actions is well depicted by the often severe skeletal damage that is observed in pituitary diseases characterized by either hypofunction or hyperfunction of the gland. Based on these findings, a novel area of research and of clinical activity has developed in recent years that has been defined as "neuroendocrinology of bone."
This review highlights the mechanisms of pituitary hormone actions in bone and the peculiar clinical and therapeutic aspects concerning skeletal fragility occurring in patients affected by excess and defect of pituitary hormones.
Regulation of Bone Metabolism
Bone cells and local environment Bone remodeling is necessary to maintain calcium homeostasis and to remove potentially damaged old bone, whereas bone modeling is a process of uncoupled bone formation and bone resorption (, ), often regulated by mechanical forces to maintain bone shape and mass.
Osteoclasts and osteoblasts are the cellular components of basic multicellular units in which coordinated bone resorption and formation of skeletal tissue occur (). Osteoclasts are multinucleated cells arising from mononuclear precursors of the hematopoietic lineage responsible for bone resorption, a process that takes  to  weeks. Thereafter, the resorbed surface attracts osteoblasts that fill the basic multicellular units with new matrix, in a process that takes  to  months to be completed. Osteoblasts derive from mesenchymal cells that reside in the bone marrow and they can differentiate further into lining cells or into osteocytes, or they can die by apoptosis (-). Osteocytes have cytoplasmic processes that connect them to form a communicating network that plays a role in maintaining the material properties and structural strength of bone ().
The differentiation and function of cells of the osteoblastic and osteoclastic lineages are regulated by systemic and local signals, and the balance of their activities is essential to maintain bone remodeling.
Bone morphogenetic proteins (BMPs) and Wnt play a fundamental role in determining osteoblastogenesis and, ultimately, in the gain of bone mass (-). Wnt and BMPs have similar effects, but signal through different pathways. BMPs are members of the TGF-b superfamily of polypeptides, which includes TGF-bs, activins, and inhibins (), acting on two groups of BMP receptors using small mothers against decapentaplegic and the MAPK signaling pathways (-). The effects of BMPs are modulated by BMP antagonists, such as noggin and gremlin, which bind BMPs, preventing their intracellular signaling. Wnts constitute a family of secreted glycoproteins that use the canonical Wnt/b-catenin signaling pathway (). When Wnt receptor binding interactions are absent, b-catenin is phosphorylated by glycogen synthase kinase-b and degrades in the proteasome. Following the binding of Wnt to specific receptors, called frizzled, and to the low-density lipoprotein receptor-related protein (LRP) coreceptors  and , the activity of glycogen synthase kinase-b is inhibited, leading to the stabilization of b-catenin and its translocation to the nucleus, where it associates with transcription factors to regulate gene expression. By inducing runtrelated transcription factor  (Runx) and osterix, which are required for osteoblastogenesis, Wnt can enhance bone formation (, ). Wnt activity is modulated by antagonists, such as secreted frizzledrelated protein (sFRP), Dickkopf- (DKK-), and sclerostin ( Fig.  
) ().
Notch is a family of transmembrane receptors regulating cell fate decisions. In immature cells of the osteoblastic lineage, Notch suppresses cell differentiation (Fig. ) by inhibiting Wnt signaling and by interacting with Runx to prevent osteoblast maturation (). This effect may be counterbalanced by decreasing the expression of sclerostin in osteocytes (). Notch inhibits osteoclastogenesis, whereas Notch by interacting with nuclear factor kB induces osteoclast differentiation ().
Osteoclast and osteoblast activities are coordinated through the receptor activator of nuclear factor kB ligand (RANKL)/osteoprotegerin (OPG) axis (Fig. ) (, ). RANKL and macrophage colony-stimulating factor (M-CSF) are required for osteoclastogenesis, and RANKL activity is opposed by OPG, a soluble decoy receptor. Proinflammatory cytokines such as TNF-a, IL-, and IL- stimulate osteoclast formation, activation, and survival ( Fig. ) (). Osteoblasts and osteoclasts can communicate with each other also through direct cell-cell contact using the ephrin receptor/ephrin system (). The tyrosine kinase receptor ephrin and its ligand ephrin are transmembrane proteins, both of which can initiate the signaling cascades (). An interaction between ephrin type-B receptor  expressed in osteoblasts and ephrin-B in osteoclasts was reported to inhibit osteoclastogenesis while stimulating osteoblastogenesis through a bidirectional signaling, thereby inducing the transition from bone resorption to formation (). Additionally, an upregulation of cyclooxygenase- in osteoblasts may lead to overproduction of prostaglandin E  (PGE), which in turn enhances osteoclastic bone resorption ( Osteocytes play multifunctional roles in orchestrating bone remodeling by regulating both osteoblast and osteoclast function by secretion of IGF-I, FRP-, DKK-, sclerostin, and RANKL ( Fig. ) (, ). Furthermore, osteocytes act as mechanosensors to control adaptive responses to mechanical loading of the skeleton, and they may be a key target cell for the actions of PTH in bone.
Calcium homeostasis
More than % of calcium in the body is stored in the skeleton as hydroxyapatite, which provides skeletal strength and is a source of calcium for the multiple calcium-mediated functions as well as for the maintenance of serum calcium within the normal range. Calcitriol (,-dihydroxyvitamin D  [,(OH)  D  ]), the hormonally active form of vitamin D, is the major controlling hormone of calcium absorption in the distal as well as the proximal intestine (). ,(OH)  D  has been reported to regulate every step of the intestinal ESSENTIAL POINTS · Vertebral fractures are a frequent complication of pituitary diseases · Diagnosis of skeletal fragility in patients with pituitary diseases may be a clinical challenge, because dual-energy X-ray PTH Besides the effects on calcium homeostasis, PTH directly influences bone remodeling. PTH signals through the PTH receptor, a G protein-coupled protein, which mediates most of the functions of PTH and of its evolutionary relative, PTH-related peptide. Following an interaction with its receptor, PTH activates the cAMP-dependent protein kinase A and the calcium-dependent protein kinase C signaling pathways to regulate the function of osteoblasts (). PTH can also activate the MAPK and phospholipase A and D pathways, and the pathway used depends on the target cell and its stage of differentiation.
The intermittent administration of low-dose PTH, in vivo and in vitro, results in enhanced osteoblastogenesis by its direct effects on cells of the osteoblast lineage and indirect effects through the induction of IGF-I and suppression of sclerostin secretion and Notch signaling (Fig. ) (). This results is an enhancement of Wnt signaling (). Interestingly, there is recent evidence that PTH directs bone marrow mesenchymal cell fate toward osteoblastogenesis, decreasing adipogenesis ().
PTH rapidly stimulates RANKL in vivo and in vitro and stimulates the ability of mature osteoblasts to promote osteoclastogenesis (-). In acute circumstances, this effect is blunted by an increase in OPG expression induced by PTH. However, prolonged exposure ( hours) to PTH inhibits OPG expression, maintaining the induction of RANKL expression (-). These effects on the RANKL-OPG axis may explain the differential effect of short vs prolonged exposure to PTH with respect to the balance of its anabolic and catabolic actions.
Sex hormones
Estrogens and androgens promote the acquisition of bone mass during puberty and are responsible for the sexual dimorphism of the skeleton (). Estrogen and androgen receptors have been detected in several cell types along the differentiation process of mesenchymal and myeloid precursors to osteoblasts and osteoclasts (). Both estrogens and androgens suppress bone resorption (Fig. ) . Indeed, the effects of estrogens are mainly direct on osteoclasts, whereas the effects of androgens seem to be indirect, by mechanisms still not completely clarified (). In fact, the levels of RANKL and OPG were not altered by androgen receptor deletion in osteoblasts and osteocytes (), suggesting that other factors are responsible for the antiresorptive effects of androgens. Estrogens suppress osteoclastogenesis and bone resorption by increasing the expression of the Wnt coreceptor LRP as well as b-catenin in osteoclasts (). Moreover, there is evidence that estrogens promote osteoclast apoptosis likely by increasing the transcription of the Fas ligand gene (). Contrary to these effects on osteoclasts, there is extensive evidence from studies in humans and rodents showing that both estrogens and androgens attenuate osteoblast and osteocyte apoptosis (, ).
Thyroid hormones
Thyroid hormones have physiological stimulatory effects on bone remodeling and bone mineralization, and normal euthyroid status during childhood and adolescence is required for acquisition of peak bone mass (). T is the active hormone produced by the thyroid gland and by peripheral deiodination of T. Interestingly, the activating enzyme type  iodothyronine deiodinase is expressed in osteoblasts (, ). Both thyroid hormone receptor-a and -b are expressed in bone, with the former receptor transcripts being at least -fold greater than those of thyroid hormone-b receptor ().
The effects of thyroid hormones on bone are considerably variable mainly in relationship with stage of differentiation and hormone levels. Experimental models indicate that T has anabolic action during skeletal development but catabolic effects in adult bone (, ). Moreover, thyroid hormone excess, even when it is mild as in subclinical hyperthyroidism, can cause bone loss by increasing bone resorption (, ).
T stimulates osteoblast proliferation and differentiation (Fig. ) , increasing expression of several proteins, such as osteocalcin, osteopontin, type I collagen, alkaline phosphatase (ALP), IGF-I, IGFbinding protein (IGFBP)-, and IGFBP- (). T may also potentiate osteoblast responses to PTH () by modulating expression of the PTH receptor ().
Osteoclasts express thyroid hormone receptor-a and -b mRNAs, but it is not clear whether functional receptors are expressed in these cells. Indeed, it is unclear whether T acts directly in the osteoclast lineage or whether its stimulatory effects on osteoclastogenesis and bone resorption are secondary responses to direct actions of T in osteoblasts, osteocytes, stromal cells, or other bone marrow cell lineages ().
Glucocorticoids
Endogenous glucocorticoids are important positive regulators of mesenchymal cell differentiation and function. In vitro studies have demonstrated that glucocorticoids are essential for the differentiation of mesenchymal cells (usually derived from bone marrow) into mature osteoblasts (), whereas there is no evidence that glucocorticoids may act directly on osteoclast formation and activity at physiological levels (). Of note, glucocorticoids are contained in all osteogenic culture media (). Calvarial cell cultures overexpressing b-hydroxysteroid dehydrogenate type  enzyme, which inactivates cortisol in cortisone, were resistant to glucocorticoids and exhibited greatly reduced osteoblastogenesis and predominant adipogenesis when compared with wild-type cultures (). This phenotypic shift was accompanied by suppression of the Wnt/b-catenin pathway and an increase in mRNA expression for sFRP-, a Wnt signaling pathway inhibitor (). These in vitro effects were consistent with the data from transgenic mice overexpressing b-hydroxysteroid dehydrogenate type  enzyme in mature osteoblasts and osteocytes that exhibited vertebral (but not femoral) trabecular osteopenia ().
The effects of glucocorticoids on bone are biphasic. When osteoblasts are exposed to glucocorticoid excess, an impaired differentiation of bone marrow stromal cells toward cells of the osteoblastic lineage is observed (). Mechanisms include the induction of peroxisome proliferator-activated receptor g, the regulation of nuclear factors of the cytosine-cytosine-adenosineadenosine-thymidine (CCAAT) enhancer-binding protein family (, ), inhibition of Wnt/b-catenin signaling, and repression of BMP- (, ). Glucocorticoids in excess may also induce apoptosis in osteoblasts and osteocytes due to activation of caspase  (, ). Interestingly, glucocorticoids in excess may affect also the metabolism and function of osteocytes, modifying the elastic modulus surrounding osteocyte lacunae and causing reduced mineral-to-matrix ratios in the same areas with an increase in lacunar size (). These effects of glucocorticoids on osteoblasts and osteocytes might account for a disproportionate loss of bone strength in relationship to bone mass in patients with glucocorticoid-induced osteoporosis () (see "Bone Density and Quality as Predictors of Fractures in Pituitary Diseases" below).
Besides the effects on osteoblasts and osteocytes, glucocorticoid in excess can early induce an increase in bone resorption mediated by an increase in expression of RANKL (), M-CSF (), and receptor subunits for osteoclastogenic cytokines of the gp family (). The proresorptive effects of glucocorticoids in excess may be mediated also by upregulation of matrix metalloproteinases that cleave collagen fibrils ().
Glucocorticoid excess may also cause indirect negative effects on bone by inhibition of GH and gonadotropin secretion, leading to functional GH deficiency (GHD) and central hypogonadism (, ). When glucocorticoid levels exceed the physiological range, an increase in hypothalamic somatostatin tone may occur with consequent impairment of GH secretion (). This inhibitory effect on pituitary GH secretion was observed even when the glucocorticoid excess was mild, as in patients treated with inhaled corticosteroids () and in those with "subclinical" endogenous hypercortisolism (). Exposure to glucocorticoid excess is also associated with qualitative abnormalities of PTH secretion, consisting of a decrease in the PTH tonic secretory rate and concomitant increase in fractional pulsatile PTH secretion (), with possible pathophysiological and clinical implications for the glucocorticoid-induced osteoporosis ().
Exposure to glucocorticoid excess is also associated with abnormalities in calcium phosphate homeostasis caused by impairment of vitamin D metabolism and activity, decreased intestinal calcium absorption, and increased renal calcium loss ().
Clinical Skeletal Endpoints and Diagnostic Tools
Markers of bone formation are enzymes and proteins produced by osteoblasts during various phases of their development and reflect different aspects of osteoblast function. Type I collagen is an important component of bone matrix, and osteoblasts secrete its precursor procollagen molecule during bone formation. In contrast, degradation products of type I collagen are released during bone resorption. Osteocalcin, bonespecific ALP, and procollagen type I N propeptide are variably considered as markers of bone formation, whereas carboxyl-terminal cross-linking telopeptide of type I collagen (CTX) in serum, collagen type I crosslinked N-telopeptide (NTX), and tartrate-resistant acid phosphatase (TRAP) are markers of bone resorption. The current guidelines recommended procollagen type I N propeptide and CTX as reference markers of bone formation and resorption, respectively, to be used in the clinical practice generally for monitoring treatment of osteoporosis with bone-active drugs (, ). In pituitary diseases, such as in other forms of secondary osteoporosis, measurement of biochemical markers of bone turnover may also provide information on the type of skeletal disorder (i.e., increase or decrease in bone turnover) caused by pituitary hormone excess or deficiency ().
In clinical practice, measurement of bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck by dual-energy X-ray absorptiometry (DXA) is the mainstay for diagnosis of osteoporosis and prediction of fracture risk (). Skeletal demineralization is graded according to the World Health Organization criteria based on comparisons of a patient's BMD with the average for young adults, after adjusting for race and sex. A T score less than or equal to 2. SD at the hip or spine is defined as osteoporosis, whereas osteopenia is defined as a T score between 2 and 2. SD (). These densitometric definitions are applicable only for postmenopausal women and men $ years of age, whereas for younger subjects the z score (i.e., the number of SDs from age-matched controls) of #2. is used to define a BMD "below the expected range for age" (). Because pituitary diseases often occur in men , years of age and premenopausal women, diagnosis of osteoporosis cannot be easily performed on the basis of BMD alone in this clinical setting. Moreover, patients with pituitary diseases were shown to fracture even in the presence of normal BMD, consistent with the concept that bone quality more than bone quantity is affected by pituitary hormones excess and defect ().
BMD measurement by DXA has significant limitations due to its bidimensional nature and the lack of compartment-specific bone density measurement (). In fact, DXA measurement of BMD does not provide information on bone quality, which depends on bone macrostructure, microstructure, mineralization, microdamage, and collagen status. Many of the limitations of areal DXA measurement can be overcome by performing high-resolution peripheral quantitative CT (HR-pQCT) at the distal radius and tibia. This technique allows higher spatial resolution, improved delineation of bone architecture, and acquisition of near isotropic volumetric dataset (, ). The main structural parameters acquired by HR-pQCT are trabecular bone volume fraction [bone volume/ trabecular volume (BV/TV)], trabecular number (Tb.N), mean trabecular thickness, mean trabecular separation, cortical thickness, and cortical porosity. In addition to measuring bone structure, HR-pQCT images may be used to obtain estimates of bone mechanical properties by finite element analysis (). Finite element analysis utilizes the structural data contained within HR-pQCT images to predict how the bone would respond to a simulated load, allowing for the estimation of bone stiffness and strength (). A simpler and more feasible technique to identify deterioration of trabecular bone microstructure is the measurement of trabecular bone score (TBS) that is a gray-level textural metric that can be extracted from the two-dimensional lumbar spine DXA image. TBS captures the mean rate of pixel gray-level variations in the DXA image. A high TBS value reflects better bone structure, whereas a low TBS value indicates worse, fracture-prone microarchitecture (). The newest method for clinical evaluation of bone mechanical properties is the reference point indentation consisting of inserting a probe through the skin and the periosteum of the proximal tibia and then performing indentation testing (). Using the OsteoProbe, the main outcome measure is bone material strength index, defined as  times the ratio of the distance the probe is able to indent a polymethyl methacrylate standard divided by the sample indentation distance ().
Vertebral fractures (VFs) are the hallmark of osteoporosis, being the most common fragility fractures (). In .% of cases, VFs occur without specific clinical symptoms, and the radiological and morphometric approach has emerged as the method of choice for evaluating the true prevalence and incidence of these fractures in clinical practice (). VFs are identified marking the vertebral body with  points to describe the vertebral shape and heights. According to the quantitative morphometric approach, VFs are defined as mild, moderate, and severe based on a height ratio decrease of % to %, % to %, and .%, respectively (). Quantitative morphometry is usually performed on spinal X-ray images, although a quantitative approach may also be applied to images of the spine acquired by DXA ().
Physiology and Pathophysiology of Pituitary Hormone Action in Bone

GH/IGF-I axis
Physiological aspects GH is a single-chain peptide of  amino acids synthesized by the pituitary gland under the control of central and peripheral signals (). The synthesis and release of GH are promoted by GH releasing hormone and inhibited by somatostatin, and they are regulated by a negative feedback mechanism (). IGF-I, which is secreted by the liver under GH control, inhibits GH secretion directly in somatotrophs and indirectly by stimulating the release of somatostatin ().
GH circulates bound to a GH-binding protein, protein generated by proteolytic cleavage of the extracellular domain of the GH receptor (GHR), or by mRNA splicing ().
IGF-I is the mediator of most effects of GH on peripheral tissues. IGF-I is produced by the liver and circulates as part of a -kDa complex formed by one molecule each of IGF-I, IGFBP-, the predominant circulating binding protein, or IGFBP- and the acid-labile subunit (). The -kDa ternary complex stabilizes IGF-I, prolonging its circulating half-life and regulating its availability to target tissues (). There are six IGFBPs, and IGFBP-, -, -, and - also can bind IGF-I in the circulation and peripheral tissues, where they regulate the availability and activity of IGF-I ().
IGF-I also is synthesized in multiple extrahepatic tissues, where it acts as a local growth factor under the control of diverse hormones and growth factors (). In chondrocytes, IGF-I synthesis is under GH control, whereas in osteoblasts its synthesis is fundamentally under the control of PTH (Fig. ) (, ) . Indeed, IGF-I mediates selected anabolic actions of PTH in bone (), reproducing selected effects of PTH on cell proliferation and survival (). Estrogens increase and glucocorticoids decrease IGF-I transcription in osteoblasts (-). Thyroid hormones increase IGF-I synthesis by osteoblasts, and IGF-I can mediate anabolic actions of T in bone ().
IGFBPs are synthesized by bone cells. IGFBP- and - expression is highest in the proliferative phase, whereas IGFBP-, -, and - expression is maximal during terminal cell differentiation of osteoblasts (). The regulation of IGFBP expression during osteoblastic cell differentiation may be related to the relative levels of autocrine and paracrine factors present in the cellular environment (). IGF-I increases IGFBP- expression by the osteoblast, whereas growth factors with mitogenic activity inhibit IGFBP- and stimulate IGFBP- expression (, ). Systemic hormones also regulate IGFBP synthesis in a cell-and culture condition-dependent manner (). GH increases IGFBP-, and cAMP inducers increase the synthesis of IGFBP-, -, -, and - in osteoblasts (), whereas glucocorticoids inhibit the synthesis of IGF-I and IGFBP-, -, and - and increase the expression of IGFBP- in osteoblasts (, ). The abundance of IGFBPs and the availability of IGF-I are regulated by metalloproteinases and serine proteases secreted by osteoblasts (, ).
GH signals through the GHR belonging to the superfamily of cytokine receptors of type . The GHR in its final form consists of an extracellular, transmembrane, and intracellular domain, whereas the ghr gene consists of nine exons encoding the receptor protein and several additional untranslated exons (). To date, two isoforms of human GHR have been identified: a full-length GHR isoform retaining the protein fragment encoded by exon , and an exon -deficient GHR (d-GHR) isoform excluding this fragment (). Exon  encodes a segment in the extracellular domain of the receptor. Although both of the isoforms retain the capacity of binding GH with a high affinity, there may well be significant functional differences between the two isoforms ().
GHR is expressed by chondrocytes and osteoblasts (-) under the control of IGF-I () and "Patients with pituitary diseases were shown to fracture even in the presence of normal BMD."
IGFBPs (, ). Binding of GH to GHR, dimerization [which may also occur before GH binding ()], and internalization of the receptor are required to initiate signaling, primarily by the activation of the Janus tyrosine kinase , signal transducer and activator of transcription (), and ERK and ERK (-), which in turn modulate the activity of Runx, which is an intracellular protein required for osteoblast cell differentiation (, ). Interestingly, GH signaling may be modulated by IGF-I receptor (IGF-IR) activation (, ).
IGF-I signals through the IGF-IR, a transmembrane glycoprotein tetramer with ligand-activated tyrosine kinase activity. Upon ligand binding, the IGF-IR dimerizes and undergoes autophosphorylation, leading to the activation of insulin receptor substrate (IRS)- and IRS- (). IRS- and - mediate the effects of IGF-I in osteoblasts. IGF-I utilizes the phosphatidylinositol -kinase pathway, which induces the activation of protein kinase B (Akt), and the MAPK pathway, which activates p, Jun N-terminal kinases, and ERK/ (, ). The usage of each pathway is dependent on culture conditions and the stage of cell differentiation. IGF-IR number and affinity are regulated by hormones and growth factors, such as platelet-derived growth factor, glucocorticoids, and ,(OH)  D  ().
Skeletal effects of GH, IGF-I, and IGFPBs
In vitro/ex vivo studies. GH can directly stimulate proliferation of osteoblasts (, , ) (Fig. ) , although most of the effects in vivo are mediated by IGF-I (). An important effect of GH is the stimulation of osteoblastogenesis in opposition to adipogenesis () by downregulating the expression of fetal antigen- (, ). GH also stimulates the expression of BMPs (Fig. ) , which are important for the differentiation of osteoblasts and for bone formation (, ). In addition to its effects on the differentiation of cells of the osteoblast lineage, GH stimulates, either directly or indirectly through IGF-I, the differentiated function of the mature osteoblast. In fact, GH stimulates the carboxylation of osteocalcin, which is a marker of osteoblastic function () and production of OPG and its accumulation in the bone matrix ( Fig. ) (, ) .
IGF-I has a double effect on osteoblast differentiation and function (Fig. ) . During the early stages of osteoblast differentiation, IGF-I induces autophagy by activation of AMP-activated protein kinase, a cellular modulator of energy availability (). The effects of IGF-I on osteoblast differentiation may also be mediated by activation of mammalian target of rapamycin (mTOR) through the phosphatidylinositol -kinase/Akt pathway (, ). Because mTOR has emerged as a key regulator of cell migration and chemotaxis (), IGF-I may have a role in recruitment of mesenchymal stem cells in the coupling process during bone remodeling. Indirectly, IGF-I may favor osteoblastogenesis by stabilizing b-catenin, a signaling molecule used by the Wnt canonical signaling pathway (). Besides favoring osteoblast differentiation, the main effect of IGF-I is on function of mature osteoblasts (). IGF-I upregulates type I collagen transcription and decreases the synthesis of collagenase  or matrix metalloproteinase , a collagen-degrading protease (), guaranteeing the maintenance of appropriate levels of bone matrix and bone mass. Less clear is the function of IGF-I on osteoclasts, which express IGF-IR (). In vitro, IGF-I induces RANKL synthesis and, as a consequence, osteoclastogenesis (). The induction of RANKL by IGF-I may explain the stimulatory effects of IGF-I on bone resorption, which may be tempered by GHinduced secretion of OPG (Fig. ) () .
IGFBP- in the skeleton has recently received attention for its stimulating effects on osteoblastogenesis (Fig. ) . In cultures from bone marrow stromal cells of igfbp- 2/2 animals at  weeks of age, the number of ALP-positive colony-forming units was significantly lower as compared with those obtained from wild-type littermates (), and the time course of differentiation was prolonged in cultures from the igfbp- 2/2 mice, with only .% of cells completing differentiation by day  (). Similarly, the amount of mineral as measured by von Kossa staining was less in the igfbp- 2/2 than in the igfbp- +/+ controls (). Interestingly, the male and female igfbp- 2/2 cultures showed comparable responses in contrast with those seen in vivo (see the next section below) (). In contrast, overexpression of igfbp- in MC-T cells significantly enhanced osteocalcin, ALP, and Wntb expression, thereby reflecting the acceleration of osteoblast differentiation (). Interestingly, a cooperative interaction between the receptors of IGFBP- and IGF-I was demonstrated leading to a coordinated series of intracellular signals required for osteoblast differentiation (). When nonadherent marrow cells from male igfbp- 2/2 mice were cultured in M-CSF and RANKL, the numbers of TRAP + osteoclasts were also significantly lower as compared with the controls ().
IGFBP-, which is highly expressed in adipocytes and osteoblasts, is the smallest IGFBP reported to be an inhibitor of IGF signaling in vitro in several cell culture models (, ), despite the conflicting results in vivo (see the next section below). In cells isolated from igfbp- 2/2 female mice, there was an increase in osteoblastogenesis and osteoclastogenesis as compared with the wild-type control (), whereas overexpression of igfbp- in osteoblasts decreased bone formation (). These findings support the hypothesis that IGFBP- inhibits the differentiation of progenitor cells and the functions of osteoblasts and osteoclasts antagonizing IGF-I signaling (Fig.  ) . Similarly, constitutive overexpression of igfbp- inhibited osteoblastic cell function, whereas the expression of igfbp- fragments had no stimulatory or inhibitory activity (). IGFBP- can inhibit or stimulate IGF activity, the latter by upregulating IGF-I delivery to cell surface receptors (). The functions of IGFBP- and IGFBP- in skeletal tissue are still unclear ().
In vivo studies (animal models). Studies on mice carrying mutations of the gh-releasing hormone receptor (lit/lit mouse) or the ghr have provided remarkable insights into the effects of low systemic IGF-I on the skeleton (, ). The phenotype of these mice is characterized by osteopenia and reduced cortical bone, but normal trabecular bone (). Similarly, mice carrying a liver-specific igf-I deletion display a modest skeletal phenotype, characterized by a decrease in cortical volume, secondary to a reduction in periosteal bone formation (). Igf-I-null mice also exhibit a low number of functional osteoclasts, indicating that IGF-I is required for normal osteoclastogenesis ().
IGF-I is locally synthesized in bone under multiple signals in part independent from GH regulation. In mice with conditional deletion of igf-Ir in osteoblasts, low osteoblast number and function, which cause reduced bone formation and trabecular bone volume, have been reported ().
The physiological function of IGF-I on skeletal homeostasis was confirmed by the study of mice carrying deletions of the signaling molecules IRS- and -. Irs--or Irs--null mice exhibit osteopenia (, ). However, their phenotypes are not identical, and irs--null mice display low bone turnover osteopenia and failure to exhibit an anabolic response to PTH, whereas irs--null mice have osteopenia with increased bone resorption, and they display a bone anabolic response to PTH (, ). The stimulatory effect of PTH on bone formation in vivo was also not observed in igf-I-and igf-Ir-null mice (, ).
Conversely, in a giant bovine GH transgenic mice model, bone length and size were increased but trabecular bone architecture was severely deteriorated with lower TB/TV and Tb.N, smaller mean trabecular thickness, and loss of intertrabecular connectivity (). Interestingly, cortical bone thickness was also significantly decreased at tibiae and vertebrae levels despite an increase in total cross-sectional area ().
There are animal models investigating the effects of IGFBP-, -, and - on the skeleton. Igfbp--null mice exhibited sex-specific changes in bone turnover and structure (). The igfbp- 2/2 males showed % lower osteocalcin levels whereas igfbp- 2/2 females showed % higher serum osteocalcin levels compared the wild-type controls. At  weeks, male but not female Igfbp- 2/2 mice showed an % reduction in distal trabecular BV/TV compared with igfbp- +/+ mice as the main effect of reduced trabecular thickness. At  weeks, male igfbp- 2/2 mice had significantly fewer osteoblasts per bone perimeter and osteoclasts per bone perimeter with marked reduction in mineralizing surface per bone. Likewise, the bone formation rate per bone surface per day was reduced by % as an effect of IGFBP- deletion (). A possible mechanism for the sex-specific effect of igfbp- deletion was the persistently higher circulating IGF-I concentrations in the female igfbp- 2/2 mice at  weeks of age but not in the male igfbp- 2/2 mice (). In rats, recombinant IGFBP- in combination with IGF-II has been shown to stimulate bone formation and protect against ovariectomy and unloading-induced bone loss ().
The in vivo effects IGFBP- on the skeleton were evaluated in mice with deletion () or conditional hyperexpression of igfbp- and in mice treated with recombinant IGFBP- (). Inconsistent with the in vitro studies, trabecular BV/TV and thickness in the distal compartment of the femur were significantly decreased in igfbp- 2/2 females when compared with littermate controls. Significant reductions were also observed in cortical area fraction and cortical thickness at the femur midshaft. In contrast, igfbp- 2/2 males had significantly higher Tb.N and connectivity density than did littermate controls, despite showing no change in trabecular BV/TV and thickness (). Interestingly, the number and surface of osteoblasts were modestly increased with the deletion of igfbp- in females, but the number and surface of osteoclasts were also markedly higher, leading to a significant increase in eroded surface in igfbp- 2/2 females. Based on the evidence that estrogen could regulate igfbp- transcription (, ), it was hypothesized that the bone loss observed in female igfbp- 2/2 mice might be related to an alteration in estrogen regulation of IGFBP- ().
Conditional hyperexpression of igfbp- in osteoblasts induced decreases in bone formation rate and mineral apposition rate, associated with a significant reduction in osteoid volume, osteoid surface, osteoblast surface, and the number of osteoblasts ().
Systemic administration of wild-type recombinant IGFBP- increased bone formation markers in serum and bone extract in a dose-dependent manner by increasing IGF bioavailability via an IGFBP- protease-dependent mechanism ().
IGFBP- is a major component of the circulating IGF complex, and its concentrations are GH-dependent (, ). The constitutive and ubiquitous overexpression of igfbp- in vivo caused growth retardation and osteopenia ().
In summary, the current experimental observations suggest that most of the effects of GH on bone are mediated by IGF-I. Systemic IGF-I is necessary to maintain cortical bone structure, whereas skeletal IGF-I appears to play a more significant role in the maintenance of trabecular bone (). These effects support the evidence that patients with GHD may develop bone loss and fractures (see "GHD" under "Hypopituitarism" below) and explain the favorable effects of recombinant human GH (rhGH) on skeletal end-points (see "Treatment options" under "Treatment of hypopituitarism" below). However, when the skeleton is chronically exposed to an excess of IGF-I, abnormalities in bone microstructure may occur with consequent decrease in bone strength (Fig. ) , explaining the high risk of VFs observed in patients with acromegaly (see "GH-secreting adenoma in adults (acromegaly)" under "Hyperfunctioning pituitary diseases" below). IGFBP- and IGFBP- were shown to exert opposite effects on osteoblasts and osteoblastogenesis at least in in vitro conditions. The clinical relevance of the IGFBPs skeletal effects in humans are still unclear ().
Prolactin
Physiological aspects
Prolactin (PRL) is a single-chain polypeptide of  amino acids (molecular mass of  kDa) primarily synthesized and secreted by lactotrope cells in the anterior pituitary gland (). PRL is secreted in different forms depending on posttranslational glycosylation, proteolysis, and phosphorylation processes (). The phosphorylated PRL form represents~% to % of the PRL released by the anterior pituitary gland with both agonistic and antagonistic properties. Moreover, PRL fragments may derive from postsecretion proteolytic cleavage of full hormone. Finally, large forms of PRL hormone may result from dimerization and multimerization processes. Secretion of PRL from the pituitary gland is regulated by endocrine, paracrine, and autocrine factors, involving neurotransmitters, neurohormones, neuropeptides, metabolic substrates, and systemic hormonal signals. PRL secretion is predominantly under hypothalamic dopaminergic control ().
PRL acts on a specific receptor (PRLR) belonging to the superfamily of cytokine receptors of type , which also includes the GHR and IL- receptor (). Several isoforms of human PRLR have been identified, including the full-length receptor and at least eight other variants depending on the different splicing in the gene transcription. The long PRLR is the major form that transmits PRL signaling, whereas the short isoforms, when coexpressed with the long isoform, can act as dominant negatives.
As a member of the cytokine receptor family, PRLR consists of an extracellular binding domain, a single transmembrane domain, and an intracellular domain required for signal transduction that lacks intrinsic kinase activity. The extracellular segment of PRLR is homologous to GHR, whereas the intracytoplasmic segments of PRLR are different and shorter than those of GHR. After binding, PRL induces receptor dimerization that is needed for intracellular signal transmission, being the Janus tyrosine kinase /signal transducer and activator of transcription pathway, the main signaling cascade. Other signals used by PRLR include the pathways of the MAPK, second messengers phosphatidylinositol and calcium channels.
PRLRs are present in the mammary glands, ovaries, pituitary gland, heart, lung, thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus, skeletal muscle, skin, and areas of the central nervous system, supporting the concept that PRL may exert physiological effects on several tissues and organs ().
Skeletal effects of PRL
In vitro/ex vivo studies. Normally, osteoblasts constitutively express PRLR, although there are some osteoblastic cell lines, for example, human osteoblastic lines, that require mediators such as ,(OH)  D  or glucocorticoids for PRLR expression ().
In osteoblast-like UMR cells exposed to high PRL concentrations corresponding to those physiologically observed during pregnancy and lactation (i.e., between  and  ng/mL), expression of cytokines and molecules involved in regulating osteoclastogenesis (i.e., RANKL, ephrin-B, TNF-a, IL- and cyclooxygenase-) was upregulated in a dose-dependent manner () (Fig.  ) . At higher pathological concentrations (i.e.,  ng/mL), PRL was also shown to downregulate OPG mRNA levels in osteoblasts, thereby further enhancing the RANKL action on osteoclasts () (Fig. ) . No direct effects of PRL on osteoclasts were demonstrated.
In addition to the PRL-induced activation of osteoclasts through osteoblasts, PRL also suppressed preosteoblast differentiation and osteoblast functions, for example, osteocalcin expression and ALP activity (Fig. ) (-). Although a -hour exposure to  to  ng/mL PRL had no effect on the osteoblast proliferation or cell viability (), prolonged exposure to  ng/mL PRL for  to  days did inhibit osteoblast proliferation in vitro, without effects on cell apoptosis ().
In vivo studies (animal models). In animal models, PRL may influence skeletal health by three different mechanisms: () stimulation of intestinal calcium absorption; () direct effects on bone cells; and () inhibition of sex steroid production.
Studies in rats demonstrated that PRL released from the anterior pituitary gland during pregnancy and lactation was the principal calciotropic maternal hormone, which was capable of stimulating calcium absorption in the small intestine and proximal large intestine ().
The direct effects of PRL on the skeleton are dependent on the age of the animals, with net bone gain in young growing individuals () but net bone loss in adults (). Indeed, basal circulating PRL (~ to  ng/mL) is essential for the maintenance of normal bone growth and remodeling. In fact, mice carrying a germline null mutation of the prlr showed decrease in trabecular and cortical mineral apposition rates, whereas the number of resorbing cells was maintained, a situation that could lead to a diminished bone mass ().
Studies of the in vivo effects of hyperprolactinemia on bone are generally complicated by chronic estrogen deficiency caused by PRL-induced hypogonadism (, ). To achieve highly sustained high plasma PRL without the stress-induced PRL release, the anterior pituitary gland was transplanted under the renal capsule of recipient rats (, ). Only PRL was constantly secreted by the grafts, owing to the absence of the stimulatory hypothalamic signals on other pituitary hormones. Hyperprolactinemia was mild, comparable to that observed in the pregnancy, without any significant change in sex steroid hormone values in the recipients (). In this experimental model, BMD and bone mineral content were not altered, whereas bone turnover was increased, accompanied by decreases in BV/TV and Tb.N and increases in trabecular separation, osteoclast surface, and eroded surface (). Meanwhile, increases in the osteoblast surface, double-labeled surface, mineral apposition rate, and bone formation rate indicated enhanced bone formation that, however, did not overcome the increase in the bone resorption process (). Increased bone formation seen in vivo was likely due to the coupling of bone formation to bone resorption, which was absent in in vitro conditions. Alternatively, an increase in bone formation could have resulted from the increased calcium supply from the PRLstimulated intestinal calcium absorption (), which also explained the decrease in BMD observed in this model.
In summary, PRL exerts direct actions on bone remodeling with effects that were shown to be dependent on the circulating hormone values and influenced by the effects of sex hormones and calcium supply. According to the experimental data, a model could be proposed in which PRL at physiological concentrations exerts stimulating effects on bone formation (Fig. ) . When PRL values increase in the range of mild hyperprolactinemia, bone remodeling is further stimulated, with bone resorption increasing more than bone formation. When PRL values are very high, bone resorption is further stimulated, whereas bone formation is suppressed with consequent impairment of trabecular bone microstructure. There are no clinical studies specifically evaluating the direct effects of PRL at different concentrations, because in most cases the relative contributions of PRL excess and sex steroid deficiency are difficult to be discriminated. However, some clinical studies evaluating the skeletal endpoints in patients with prolactinoma seem to suggest that PRL may have a direct effect on bone in humans, such as demonstrated in experimental models (see "PRL-oma" under "Hyperfunctioning pituitary diseases" below) .
FSH
Physiological aspects
FSH is a .-kDa glycoprotein heterodimer consisting of two polypeptide units, a and b, with the latter conferring receptor selectivity to the hormone. FSH is secreted by the pituitary gland under the control of GnRH, the actions of which are modulated by several peptides (e.g., galanin) and hormones (e.g., PRL, sex hormones, activins, and inhibins) (, ). FSH exerts its biological effects binding a rhodopsin-like G protein-coupled receptor of~ kDa that has a conserved seven-transmembrane domain structure and an~ kDa extracellular hormone binding domain (). The fsh receptor (fshr) gene has been mapped to chromosome p-p and consists of  exons and  introns. The first nine exons encode the extracellular domain of the receptor, whereas exon  of FSHR encodes the C-terminal end of the extracellular domain, the entire transmembrane domain, and the intracellular domain that is fundamental for signal transduction. There are polymorphisms involving exon  with consequent variability in FSHR function and cellular response to FSH (). Specifically, there is polymorphism involving the residue  of exon  (i.e., Ser/Ser variant), making the "receptor more resistant" to FSH action than the other allelic variants, requiring stronger stimulation to obtain the same response (, ).
Signaling of FSHR appears to be mediated through Gs, the G protein mostly associated with activation of adenyl cyclase and the cAMP second messenger system. However, there are many splice variants of the FSHR that might signal by alternative mechanisms ().
Skeletal effects of FSH
In vitro/ex vivo studies. FSHR expression was demonstrated in mature osteoclasts and mesenchymal stem cells but not in mature osteoblasts (). FSH preferentially increased the number of CD + cells expressing high levels of RANK (i.e., the receptor of RANKL) that are more likely to differentiate into mature osteoclasts (). Interestingly, FSH had no significant influence on RANK expression at a concentration of  mIU/mL, which is in the range of the circulating follicular-phase FSH concentrations of women during most of their reproductive years (). However, FSH caused a significant increase in RANK expression at  mIU/mL, a concentration typical during perimenopause that is associated with increased bone loss (, ). At higher concentrations reached after menopause ( mIU/mL), FSH had less of an influence on RANK expression (). Besides stimulating osteoclast formation, FSH was shown to inhibit apoptosis of osteoclasts even in the presence of a potent proapoptotic stimulus, camptothecin (). The effects of FSH on osteoclasts were abolished by an FSH antibody ().
FSH stimulated osteoclastogenesis by rapidly enhancing the phosphorylation of Erk/, IkBa, and Akt, with effects that were shown to be less profound than those induced by RANKL (). However, RANKL and FSH induced additive effects on osteoclastogenesis, suggesting common mechanisms for downstream activation (). Besides the direct effects on osteoclasts, FSH was also shown to upregulate TNF-a and IL- production by monocytes and macrophages present in the bone marrow (-) (Fig. ) . The pro-osteoclastogenetic effects were not obtained with LH ().
Ex vivo studies revealed a reduction in osteoclastogenic and bone-resorptive activity in fshr 2/2 cultures compared with wild-type controls ().
Consistent with the absence of FSHR on osteoblasts, FSH did not increase calcein-labeled surfaces and did not alter the formation of colony-forming unit fibroblast or osteoblast ().
In vivo studies (animal and human models). The first experimental evidence that FSH may influence bone metabolism was provided by studies demonstrating that hypophysectomy blunted the bone loss induced by ovariectomy in rats (, ). Consistent with these results, fshr 2/2 and fshb 2/2 mice do not lose bone despite hypogonadism (). In fact, areal and volumetric BMD at both trabecular and cortical sites, femoral trabecular BV/TV, trabecular thickness, or Tb.N in hypogonadal fshr 2/2 mice, were indistinguishable from those of eugonadal controls (). Similarly, hypogonadal fshb 2/2 females did not lose bone, and their spinal and tibial areal BMDs were similar to those of wild-type mice (). Heterozygotic fshb 2/+ mice were eugonadal and fully fertile, with normal ovaries and uteri, but they had a % reduction in serum FSH levels. This allowed examining the effects of FSH independently of estrogen status. FSH haploinsufficiency decreased osteoclast differentiation and bone resorption with a consequent increase in spinal and femoral areal BMD compared with wildtype mice (). At the femoral neck, volumetric BMD, bone volume fraction, and Tb.N were also strikingly increased.
All of the above data suggest that FSH stimulates osteoclastogenesis and bone resorption by direct and indirect actions on osteoclasts (Fig. ) . However, the experimental models also provided evidence that the direct skeletal effects of FSH may be influenced by the gonadal function because severe hypoestrogenemia would invariably prevent full osteoprotection by FSH inhibition. In fact, when ovariectomized mice were given daily injections of the FSH antibody, a significant increase of BV/TV was observed, although the prevention of bone loss caused by estrogen depletion was not complete (, ). Alternatively, when FSH secretion was increased in transgenic mice with normal ovary function, an increase in trabecular mass was observed, likely reflecting the favorable skeletal effects of high levels of gonadal hormones (e.g., androgens and inhibin) induced by FSH stimulation ().
The relative effects of FSH and gonadal hormones are difficult to be discriminated in human physiology and pathophysiology (), although there are some conditions in which the role of FSH seems to be predominant to that of gonadal hormones. FSH is considered a reliable biomarker of the evolution from active reproductive age to and through the menopause transition to the postmenopausal period (). During late perimenopause, even before estrogen has declined, FSH levels begin to rise. This rise is accompanied by a sharp elevation in the markers of bone turnover (, ) and decrease in BMD (, ). FSH was suggested to explain .% to .% of the changes in bone resorption indicators (), and higher serum levels in biochemical markers of bone resorption were found in perimenopausal women with FSH . to  mIU/mL (). In the Study of Women's Health Across the Nation, which included  women aged  to  years, an inverse association between FSH values and BMD at the lumbar spine, femoral neck, and total hip was found (). When the analysis was performed longitudinally in  perimenopausal women of the Study of Women's Health Across the Nation, a strong correlation between changes in FSH levels and decrements in lumbar spine BMD was observed (). The rate of bone loss at the lumbar spine and femoral neck was highest during the  to  years before the final menstrual period, a time period in which FSH levels were . mIU/mL (). Of note, levels of estradiol during the menopause transition were poor predictors of decremental BMD change (). Similar results were reported in Chinese women between  and  years of age, in whom greater bone loss was observed when serum FSH values were . mIU/mL ().
Evidence apparently supporting a direct effect of FSH on bone in humans derives from evaluation of skeletal endpoints in subjects harboring an activating polymorphism of FSHR (). In fact, postmenopausal women with the AA (Asn/ Asn) rs genotype showed higher serum levels of bone-specific ALP and CTXs, lower femoral neck and total body BMD, higher prevalence of osteoporosis, and a trend of higher prevalence of fractures as compared with those with the GG (Ser/Ser) rs FSHR genotype, without any differences in estradiol between the two groups of women ().
The direct effects of FSH on bone remodeling in humans have been questioned by two clinical studies evaluating the skeletal effects of low () and high () levels of FSH. With regard to FSH in postmenopausal women using an aromatase inhibitor, the suppression of FSH secretion by a GnRH agonist did not reduce markers of bone resorption (). Similarly, acute administration of recombinant FSH in  infertile women undergoing in vitro fertilization induced a CTX decrease as an effect of high estradiol induced by ovarian stimulation ().
In summary, experimental data suggest that FSH stimulates osteoclastogenesis and bone resorption. The clinical relevance of this effect in humans is still largely uncertain, because patients with central hypogonadism are at high risk of bone loss notwithstanding low FSH values (see "Other pituitary hormone deficiencies" under "Hypopituitarism" below). However, according to data in the available literature, a model could be proposed in which high FSH may have a role in determining bone loss in women during the menopause transition, when gonadal hormones are not so low such as in the postmenopausal period when the role of hypoestrogenemia is predominant (Fig. ) . Indeed, other studies are needed to clarify whether the association between high FSH values and bone loss during the menopause transition may truly reflect a direct effect of FSH on bone rather than potentially be explained by FSH acting as a better integrated measure of ovarian function than a single measurement of serum estradiol ().
TSH
Physiological aspects
TSH is a -to -kDa glycoprotein composed of a common a subunit and a unique b subunit, with the latter being responsible for hormone specificity. TSH is primarily produced by the pituitary gland under control of neuronal input from the hypothalamus and negative feedback by thyroid hormones. However, possible extrapituitary sources of TSH have been indentified for . years (, ), and additional TSH-related circuits may be functioning in extrathyroidal sites, including the bone, where a TSHb splice variant was shown to be ectopically produced (, ).
TSH acts on the TSH receptor (TSHR), a seventransmembrane-spanning receptor that stimulates a number of different cell-signal transduction pathways (). The tshr gene is localized on chromosome q, and three germline TSHR polymorphisms, resulting in amino acid substitutions, have been identified (). Two of these are located in the extracellular domain of the receptor (AspHis and ProThr) (, ), and one is located in the intracellular domain (AspGlu) (). The TSHRGlu allele was associated with lower levels of plasma TSH in a population of healthy blood donors without effect on free T (FT) (), pointing toward a higher sensitivity of the variant vs the wildtype TSHR ().
The activation of Gas by TSH stimulates the cAMP-protein kinase A pathway whereas Gaq/ stimulates phospholipase C-mediated generation of diacylglycerol and inositol-,,-trisphosphate activating the calcium and protein kinase C pathways, involving the MAPKs ERK/, p kinases, and akt (-). Moreover, TSH causes translocation of both b-arrestin- and b-arrestin- () that are known to be important scaffolding proteins for internalization, desensitization, and activation of several G protein-independent signal transduction pathways ().
TSHR is canonically involved in regulation of synthesis and secretion of thyroid hormones from thyroid follicular cells. However, the expression of TSHR has also been reported in extrathyroidal tissues and organs, such as brain, kidney, testis, heart, adipose tissue, fibroblasts, hemopoietic cells, and immune cells (, ). In fact, several nontraditional biological roles for the TSHR have been hypothesized, such as those involving the stimulation of angiogenesis (, ) and regulation of adipogenesis (). TSHR was shown to be expressed also in bone cells, specifically during the early and middle phases of osteoclast and osteoblast formation (), and there has been accumulating evidence that TSH may have osteoprotective effects ().
Skeletal effects of TSH
In vitro/ex vivo studies. In bone marrow cells isolated from femurs and tibiae of mice, recombinant TSH (rTSH) caused a concentration-dependent inhibition of osteoclast formation (Fig. ) accompanied by a decrease in expression of TRAP, cathepsin K, calcitonin receptor, and b  integrin, as well as a decrease in resorption of dentin slices by osteoclasts (). Similar effects were produced using monoclonal TSHR antibodies at equivalent doses in murine embryonic stem cells (). Moreover, inhibition of osteoclastogenesis was observed in bone marrow cells isolated from transgenic mice overexpressing human TSHR or constitutively active TSHR in osteoclasts under a TRAP promoter (), suggesting that the antiresorptive actions of intermittent and continuous TSHR activation are in essence similar.
When cells were derived from tshr-null mice generated by deleting exon  of the mouse TSHR gene (), osteoclast formation was increased by about twofold compared with wild-type cultures, with a concomitant increase in expression of osteoclast markers TRAP and calcitonin receptor ().
The antiosteoclastogenic effects of TSH are mediated by inhibition of TNF-a production and activity in osteoclasts (Fig. ) (, ). Supernatants of bone marrow cells derived from tshr-null mice had a threefold higher concentration of TNF-a as compared with cultures from wild-type mice (). The increase in osteoclastogenesis observed in bone marrow cells deleted for TSHR was abolished by anti-TNF-a blocking antibodies () and when cells were concomitantly deleted for tnfa (). Interestingly, TNF-a failed to stimulate the pro-osteoclastogenetic pathways in cells overexpressing TSHR (), suggesting that TSH and TNF-a may compete for the same transduction pathways but with opposite effects (, ). Indeed, the interplay between TNF-a and TSH is complex. In fact, TSH was shown to inhibit and stimulate TNF-a expression in osteoclasts and osteoblasts, respectively (, ). One could argue that TNF-a produced by osteoblasts in response to TSH could potentially stimulate the production of a TSHb variant by macrophages, which in turn inhibits TNF-a production by osteoclasts, realizing a negative feedback loop potentially important for modulating the effects of TSH and thyroid hormone in physiological and pathological conditions (, ).
The role of TSH in osteoblast regulation is less defined, and the effects were shown to be rather variable (Fig. ) . In bone marrow-derived cultures, TSH inhibited osteoblastogenesis through a Runx- and osterix-independent mechanism involving downregulation of LRP, a Wnt coreceptor, and Flk, a VEGF receptor (). In parallel, the expression of both LRP and Flk was upregulated in cells deriving from tshr-null mice (). In other experimental conditions, TSH stimulated osteoblastogenesis. In fact, in embryonic stem cell cultures, TSH stimulated osteoblast differentiation primarily through the upregulation of the noncanonical Wnt components frizzled receptor and Wnta (), as well as by upregulation of IGFs and their stimulating binding proteins  and  (). The in vitro anabolic effect of TSH was marked by an increase in production of type  collagen, ALP, osteocalcin, and OPG (). Interestingly, the increase of OPG may realize a feed-forward loop inhibiting osteoclastogenesis. Although multiple pathways appear to be involved in TSHR signaling in osteoblasts (), the b-arrestin-dependent pathway seems to be the most important in stimulating the differentiation of precursor cells toward an osteoblast phenotype (), such as demonstrated for PTH (). Of note, the Gs-cAMP pathway, which is primarily involved in regulating thyroid function, was not shown to be determinant for the anabolic effects of TSH on bone (). In fact, the small molecule C that is a TSH agonist for cAMP signaling () was not able to stimulate osteoblast differentiation (). In contrast, a small molecule ligand that was functionally selective toward human TSHR activation of b-arrestin- potentiated the TSHinduced upregulation of ALP and osteopontin mRNA ().
In vivo studies (animal and human models). In a seminal study (), tshr-null mice with severe osteoporosis did not improve after treatment of hypothyroidism. Histomorphometry revealed a significant increase in TRAP-labeled surfaces in vertebral bodies, consisting of increased osteoclastogenesis caused by abrogation of TSH signaling in bone cells (). In a more recent study, mice lacking TSHR showed decreased trabecular bone volume and bone strength at distal femurs, as evaluated by biomechanical tests and compared with the wild-type littermates (). Again, the replacement of hypothyroidism did not restore normal strength in this model ().
When TSHR-deficient mice were exposed to thyroid hormone excess, osteoporosis was more severe than that observed in hyperthyroid wild-type mice (). This finding may reflect the potential osteoprotection of the TSHb variant locally produced by macrophages under the positive control of thyroid hormone excess (, ). This TSH-like molecule locally produced within bone marrow may counteract the negative effects of hyperthyroidism only in mice harboring TSHR.
The genetic ablation of TNF-a in TSHR-deficient mice rescued in a dose-dependent manner the abnormalities in bone microstructure arising from increased bone resorption (), confirming the in vitro data indicating that TNF-a is the mediator of bone damage caused by abrogation of TSHR signaling (, ).
Low doses of rTSH were shown to increase both trabecular and cortical bone volume with improved microarchitecture and mechanical strength in ovariectomized rats (, ). These effects were mediated by inhibition of osteoclastogenesis and activation of osteoblastogenesis (). This latter effect occurred  months after ovariectomy when bone turnover was low, suggesting that the anabolic effects of rTSH intermittently administered may be influenced by the bone marrow microenvironment present in low turnover osteopenic bone (). Interestingly, the doses of rTSH leading to bone effects were -to -fold lower than those used for clinical diagnostic indications ().
There is evidence that TSH may have direct effects on skeletal remodeling in humans, such as previously demonstrated in experimental animals. In fact, rTSH induced changes in biochemical markers of bone turnover in patients without a thyroid gland. In a seminal study, Mazziotti et al.
() reported for the first time a significant decrease in serum CTX values accompanied by a slight but statistically significant increase in ALP values after two consecutive doses of rTSH in postmenopausal women under postsurgical and radioiodine therapy follow-up for thyroid cancer. Of note, these effects were independent of thyroid hormones because the women did not have a thyroid gland, and replacement therapy with L-thyroxine was stable during the study period. The transient decrease in CTX values after rTSH injection was confirmed by Karga et al. () , who also reported an increase in PTH values as a possible effect of blunted bone resorption. Interestingly, Martini et al.
() showed an increase in procollagen type I Nterminal propeptide, a marker of bone formation, supporting the conclusion that bolus doses of TSH are indeed anabolic in humans, such as already demonstrated in murine models (, ). The authors also reported an increase in RANKL concentrations (), a finding not confirmed by others ().
In several clinical studies, serum TSH values in the reference range were associated with BMD and fractures. Kim et al. () showed that lumbar and femoral neck BMDs in postmenopausal women with low-normal TSH levels were significantly lower than those in subjects with high-normal TSH levels by as much as % to %, with a risk of osteoporosis that was twofold higher in the former and compared with the latter subjects. Similar results were reported by others in both women (-) and men (-). Interestingly, Lee et Likely due to higher sensitivity of TSHR (), TSHR-AspGlu polymorphism was associated with higher BMD at the femoral neck independent of thyroid status either in euthyroid subjects () or in those with subclinical thyrotoxicosis (). Notably, in this latter condition it can be difficult to discriminate the relative effects of increased thyroid hormone levels vs low TSH on bone.
The osteoprotective effects of TSH were questioned in two animal models of hypothyroidism (i.e., pax
and thyroid hormone receptor-b-null mice), in which mice were osteoporotic despite high TSH values and normal TSHR signaling in bone (). Likewise, bone loss has been sporadically reported in hyperthyroid patients with TSH-secreting adenoma (TSH-oma), despite normal or even high TSH values (see "TSHoma" under "Hyperfunctioning pituitary diseases" below). On the one hand, one could argue that these results cannot be unexpected considering the potential negative effects of long-standing high TSH values on osteoblastogenesis (, ), as opposed to anabolic effects observed with intermittent exposure to high TSH values. On the other hand, it is reasonable to hypothesize that the antiresorptive action of TSH may be overcome by the negative effects of thyroid hormone excess in patients with TSH-oma.
In summary, there is evidence that TSH may directly inhibit osteoclastogenesis and bone resorption, with concomitant increase in bone formation when hormone exposure is intermittent. Despite the unavaibility of a model in human diseases clearly demonstrating the reciprocal role of TSH and thyroid hormones on bone, a unifying view of the different clinical studies on the topic may be offered (Fig. ) . In this model a prevalent role of TSH in driving fracture risk may be hypothesized in the presence of normal thyroid hormone levels. A less relevant role for TSH may be suggested when thyroid hormones rise above the normal levels.
"The clinical relevance of all of these effects of GH excess on calcium metabolism is uncertain."
Pituitary Diseases and Skeletal Endpoints
Hyperfunctioning pituitary diseases Hyperfunctioning pituitary diseases are caused by pituitary adenomas. Epidemiologically, the most frequent of all adenomas is the PRL-secreting adenoma (PRL-oma) (% to %), followed by GH-secreting adenoma (% to %), corticotrophin (ACTH)-secreting adenoma (% to %), and TSH-oma (.% to %), with the remaining being represented by nonfunctioning pituitary adenomas.
GH-secreting adenoma in adults (acromegaly)
Clinical manifestations of acromegaly range from subtle signs of GH/IGF-I excess, such as acral overgrowth and coarsening of facial features, to significant metabolic, cardiovascular, and respiratory manifestations, leading to an increase in morbidity and mortality (, ).
Although GH and IGF-I are traditionally considered as anabolic hormones for the skeleton with favorable physiological effects on longitudinal bone growth, bone modeling, and bone remodeling, and patients with acromegaly have characteristically enlarged bones (), during the last  to  years there has been accumulating evidence that GH excess may cause skeletal fragility sustained by an increase in bone resorption and abnormalities in bone microstructure, finally leading to increased risk of VFs ().
Effects of GH hypersecretion on bone turnover and calcium metabolism. Patients with acromegaly have increased bone turnover, as determined by changes in biochemical markers, calcium kinetics, and bone histomorphometry (). In a recent meta-analysis including  studies (-), the standardized mean differences between acromegaly patients and control subjects were . and . for bone formation and bone resorption, respectively, without significant impact of sex and gonadal status (). In studies evaluating both processes of bone remodeling, the differences in bone resorption were higher than those observed for bone formation (, , , , , ), supporting the concept that bone loss occurs in acromegaly as an effect of uncoupled bone turnover ().
Despite the stimulating effects of GH and IGF-I on renal activation of vitamin D (), hypovitaminosis D has been consistently reported in patients with acromegaly (, ), and there is also evidence suggesting lower peripheral bioavailability of vitamin D in this clinical setting as an effect of an increase in vitamin D binding protein (, ). Moreover, GH excess was shown to influence PTH pulsatility with prolongation of pulse half-duration and increase in pulse mass ().
The clinical relevance of all of these effects of GH excess on calcium metabolism is uncertain. Patients with active acromegaly frequently have phosphate and calcium abnormalities, such as mild hyperphosphatemia, a tendency toward increased plasma calcium levels, and hypercalciuria independently of PTH (, ). The hypercalciuria observed in acromegaly patients is classically linked to increased intestinal calcium absorption driven by calcitriol, as well as to the increased bone turnover induced by GH excess (). Therefore, hypercalciuria may be considered, at least in part, as a marker of skeletal fragility. The elevated plasma phosphate concentrations are related both to increased calcitriol-stimulated dietary phosphate absorption and to a direct antiphosphaturic action of IGF-I in the proximal renal tubule, whereas it is uncertain whether hyperphosphatemia may correlate with high bone turnover (, ).
Effects of GH hypersecretion on BMD. DXA measurements of BMD in acromegaly may be affected by some pitfalls related to the abnormalities of bone structure caused by GH hypersecretion. Joint degenerative disorders, characterized by osteophyte formation and facet joint hypertrophy, may lead to an overestimation of BMD measured at the lumbar spine (). Moreover, DXA measurement of BMD in acromegaly could be influenced by the bone enlargement caused by GH excess (), although the effects on bone mineral content seem to overcome those on bone area (). Another aspect of mention is the different effect of GH hypersecretion on cortical and trabecular bone. In fact, pathologically high GH and IGF-I levels exert a deleterious effect on trabecular microarchitecture, whereas cortical bone density tends to be increased as an effect of GH on periostal ossification (). DXA does not distinguish between cortical and trabecular bone, and densitometric results are greatly influenced by the variable distribution of these two compartments in the different skeletal sites ().
Most patients with acromegaly show normal or even increased BMD at various skeletal sites, and osteopenia and osteoporosis are not common features in acromegaly. In a meta-analysis performed in  studies (, , , , -), acromegaly did not induce a significant change in BMD at the lumbar spine, whereas BMD was increased at the femoral neck and total hip (). Indeed, when the analysis was performed in hypogonadal patients (, , , -), BMD was low at the lumbar spine and to a lesser extent at the femoral neck (), consistent with the concept that loss of sex steroids increases bone turnover at the trabecular level, which is predominant in the spine. Moreover, the differences between lumbar spine and femoral neck BMD may be also influenced by the activity of acromegaly, reflecting the different effects of GH excess on trabecular and cortical bone ().
Effects of GH hypersecretion on risk of fractures. The results from all published studies (-, , -) on fragility fractures and bone structure in treated and untreated acromegaly are reported in Table  .
Clinical fractures. Retrospective studies did not show an increased clinical fracture risk in acromegaly (, ), likely reflecting the impossibility of questionnaires and databases to correctly identify VFs ().
Morphometric VFs-prevalence. In their seminal study, using the radiological and morphometric approach in acromegaly (), Bonadonna et al. () identified for the first time VFs in~% of postmenopausal women with acromegaly, although densitometric osteoporosis was present in ,% of the entire population. Fractures were multiple in more than twothirds of women with fractures. Three years later, our group also reported VFs in  out of  male patients with acromegaly (median age  years) (). Other cross-sectional studies confirmed these findings (, , , ), and the overall median prevalence of VFs was calculated to be~%, with a fracture risk that was threefold to eightfold higher in acromegaly patients as compared with control subjects ().
Six cross-sectional studies (, , , , , ) and three longitudinal studies (, , ) evaluated the relationship between sex and VFs in  patients with acromegaly ( females,  males;  patients with active disease); VFs were shown to be slightly more frequent in males as compared with females (Fig. ) . Moreover, in five cross-sectional studies including  patients with acromegaly ( patients with hypogonadism,  with active disease), as already reported in other forms of secondary osteoporosis (), the rate of fractures was found to be relatively increased in hypogonadal as compared with eugonadal patients (, , , , ).
The impact of underlying genetic background on fracture risk of patients with acromegaly has been controversial. Polymorphism of GHR, characterized by deletion of exon- with consequent higher sensitivity to GH, was associated with a higher prevalence of VFs in patients with acromegaly (), with stronger association in females as compared with males (). In another study performed in patients with long-standing controlled acromegaly, deletion of exon- of GHR was associated with higher prevalence of colonic polyps, dolichocolon, and osteoarthritis, without any significant impact of GHR polymorphism on BMD and vertebral and nonvertebral fractures (). The reasons for these inconsistent results are unclear, but one could argue that the presence of patients with active acromegaly in the first study may have influenced the association between GHR polymorphism and VF risk (). In fact, deletion of exon- in GHR may amplify the negative effects of GH excess on the skeleton.
Interestingly, VFs developed more frequently at the thoracic spine and they were most commonly anterior wedge fractures (), possibly contributing to kyphosis of patients with acromegaly, a feature clearly present in the first patients reported by Pierre-Marie (). Indeed, the potential clinical impact of VFs in acromegaly has so far not been investigated. However, that .% of patients with fractures were shown to have either multiple or severe VFs () suggests that VFs may be associated with an unfavorable functional outcome (), such as demonstrated in other clinical settings (-).
Morphometric VFs-incidence. The abovementioned cross-sectional studies were not able to define the causal relationship between GH hypersecretion and VFs and did not provide reliable information on the clinical predictors of fractures in this clinical setting. These limitations were also amplified by the difficulty to attribute to osteoporosis the vertebral deformity, particularly when of borderline relevance (mild vs nonfracture) and occurring in the presence of normal BMD (see "Bone Density and Quality as Predictors of Fractures in Pituitary Diseases" below). To overcome these potential shortcomings, some studies were designed to evaluate the incidence of VFs in active and controlled acromegaly (, , , ). In a retrospective longitudinal study, Battista et al. () reported incident VFs in more than a third of acromegaly patients with hypogonadism regardless of activity of disease. The first prospective study specifically evaluating the incidence and determinants of VFs in active and controlled acromegaly was pubslihed in  (). Incident VFs developed in % of patients with acromegaly during a -year follow-up, in close relationship with baseline disease status (i.e., higher incidence in patients with active acromegaly) and duration of active disease. Hypogonadism and preexisting VFs were shown to influence the fracture risk only in patients with controlled acromegaly but not in those with active disease (see "Skeletal endpoints in treated acromegaly" under "Treatment of hyperfunctioning pituitary diseases" below) (, ).
The predominant role of GH hypersecretion in determining fracture risk in acromegaly has been confirmed by a recent retrospective study evaluating the incidence of VFs in patients with active acromegaly undergoing different medical therapies (). This study reported a higher incidence of VFs in patients with active disease regardless of the therapeutic approach ().
Effects of GH hypersecretion on bone structure. In the last few years, it has clearly emerged that a high prevalence and incidence of VFs is related to increased bone turnover and deterioration of bone structure, although evidence that acromegaly may cause impairment in bone quality was already provided by Ueland et al. () in : they reported loss of trabecular connections and low trabecular bone biomechanical competence in iliac crest biopsies of  acromegaly patients ( males and  females) with active acromegaly. Only  years after, and following our report of increased VFs, many other studies confirmed that bone structure was altered in patients with acromegaly. Using HR-pQCT, Madeira et al.
() reported significant associations between several parameters of bone microstructure (i.e., BV/TV, Tb.N, and mean trabecular separation) and either gonadal or activity of disease in  patients with acromegaly ( males,  females). Because the gonadal status appeared to be an important determinant of bone properties, the authors performed a subanalysis in eugonadal acromegalic patients as compared with control subjects. Interestingly, despite the higher trabecular volumetric bone density and cortical thickness in the distal radius, acromegaly patients with normal gonadal function showed abnormalities in most of the trabecular measurements at the distal radius and distal tibia, supporting the hypothesis that compromised bone microstructure in acromegaly may occur regardless of gonadal status (). This concept was recently reinforced by Silva et al. (), who reported deterioration in trabecular microstructure of the radius in  eugonadal males with acromegaly. Besides the abnormalities in trabecular microstructure, acromegaly was shown to also affect cortical bone in terms of increased porosity (, , ) and impaired cortical strength ().
Other studies evaluated bone structure at vertebral site by measuring lumbar spine TBS. Hong et al. () found a % lower TBS in males and females with acromegaly as compared with control subjects, without any significant difference in BMD. In another uncontrolled study performed in  naive patients with active acromegaly, TBS was found to be partially degraded according to the definition by the manufacturer, whereas BMD z scores in most compartments did not differ from  ().
In summary, there is consistent evidence that GH excess causes deterioration of bone microstructure leading to high risk of VFs in close relationship with duration of active acromegaly. Bone turnover is invariably increased in patients with active acromegaly, whereas BMD as measured by DXA is generally slightly decreased or even normal.
PRL-oma
Patients with PRL-oma are predisposed to develop osteopenia, osteoporosis, and fragility fractures as an effect of hypogonadism induced by PRL excess, as well as an effect of direct actions of PRL on bone cells and calcium metabolism ().
Effects of hyperprolactinemia on bone turnover and BMD. Accelerated bone turnover is expected in patients exposed to PRL excess (), although biochemical data from clinical studies have been variable, with only few studies reporting an increase in serum levels of markers of bone formation and resorption (, ). In two studies, osteocalcin (i.e., a marker of bone formation) was shown to be suppressed whereas NTX (i.e., a marker of bone resorption) was high in adults with PRL-oma in close relationship with duration of disease and PRL levels (, ), consistent with experimental evidence that PRL may have direct and opposite effects on bone formation and bone resorption (see "Skeletal effects of PRL" under "Prolactin" above).
Men and women with PRL-oma were equally affected by bone loss (, ). Eighty percent of male patients with PRL-oma were found to have densitometric diagnosis of either osteopenia or osteoporosis at the lumbar spine, whereas only a minority of them (%) showed a low BMD at the femoral neck, suggesting that trabecular bone was damaged earlier than cortical bone (, , ). The relative effects of hypogonadism and hyperprolactinemia on BMD are still a matter of controversy (see "Skeletal effects of PRL" under "Prolactin" above). In some studies, BMD was correlated with PRL levels, biochemical markers of bone turnover, and duration of disease, but not with serum testosterone values in males () or estradiol values and coexistent amenorrhea in women (). In contrast, several other studies reported a significant association between BMD values and hypogonadism in patients with PRL-oma (, , -). The mean spinal bone density in the hyperprolactinemic amenorrheic women was significantly lower than that in eumenorrheic hyperprolactinemic women (). Therefore, it is possible to hypothesize that bone loss in patients with hypeprolactinemia may be synergistically determined by increased PRL levels per se and by the concomitant sex hormone deprivation. The PRL-oma-related bone loss can be severe and affect young patients, because it can restrict peak bone mass acquisition (). In fact, reduction of BMD was more severe in childhood-onset hyperprolactinaemic patients than in those who developed the disease in adulthood (, ). Twenty-two percent of premenopausal women with PRL-oma showed a pathological z score (i.e., a z score #2. SD) with more severe bone loss at lumbar spine as compared with femoral DXA sites ().
Effects of hyperprolactinemia on risk of fractures. Available studies (, -) on fracture risk in treated and untreated PRL-oma are reported in Table  .
Clinical fractures. Using the International Classification of Diseases codes, the Prolactin Epidemiology, Audit and Research Study did not find a significant increase in fractures in patients with PRL-oma, suggesting that this complication could be underestimated in real-life clinical practice (). In contrast, Vestergaard et al. () reported a % increase in risk of clinical fractures in PRL-oma before the diagnosis of disease as compared with controls. The annual fracture rate was .% before and .% after diagnosis among the patients with PRL-oma, and .% and .%, respectively, among their controls ().
Morphometric VFs-prevalence. Two recent cross-sectional studies reported high prevalence of radiological VFs in women and men with PRL-oma (, ). The first study was carried out in  women ( were premenopausal and  were in the postmenopausal period) who were evaluated for VFs using quantitative morphometry (). Radiological VFs were found in  out of these women (.%), with the prevalence being higher in postmenopausal women ( of ) as compared with premenopausal women ( of ). Of note, the prevalence of VFs in postmenopausal women was higher as compared with control women of comparable age, in close relationship with the duration of hyperprolactinemia (OR, .; % CI, . to .) but not with the age of onset of hyperprolactinemia (OR, .; % CI, . to .). These findings suggested that PRL excess per se may cause skeletal fragility regardless of gonadal status, although the cross-sectional design did not allow defining exactly when VFs developed in relationship with menopausal status (). In the second crosssectional study, radiological VFs were found in .% of male patients with PRL-oma, with the prevalence being about fivefold higher as compared with control subjects (). Interestingly, the prevalence of VFs was not significantly different between eugonadal and VF rate (%) hypogonadal patients, and no significant difference in serum testosterone values was found between males with or without fractures (). Again, these findings suggest that even in males PRL excess may influence fracture risk independent of gonadal status. There are no studies prospectively evaluating the incidence of VFs in patients with PRL-oma.
In summary, PRL-oma causes high bone turnover osteoporosis, with low BMD occurring in most patients, especially when the disease develops in the first decades of life before the achievement of peak bone mass. The pathogenesis of PRL-oma-induced bone loss is multifactorial, because both direct and indirect (hypogonadism) skeletal effects of hyperprolactinemia may be involved.
ACTH-secreting adenoma (Cushing disease)
In Cushing's original series of  patients published in , radiographic osteoporosis was reported in  patient,  patients were reported to have kyphosis, and  were reported to have spontaneous fractures. Indeed, skeletal fragility is a frequent complication of endogenous hypercortisolism, and fragility fractures may be the presenting clinical feature of disease (, ).
Effects of hypercortisolism on bone turnover and BMD. Differently from exogenous glucocorticoid excess (), in endogenous hypercortisolism the early and transient phase of high bone turnover is not usually evident because the diagnosis of disease is often delayed with respect to onset of hypercortisolism (). However, the biochemical skeletal phenotype may be characterized by uncoupled low bone formation and slightly increased bone resorption (-).
The prevalence of osteoporosis as assessed by DXA has been reported to be % to % (-), in close relationship with activity of disease as assessed by measurement of urinary cortisol values (, ). The bone loss was more pronounced at the lumbar spine and femoral neck, consistent with the view that trabecular bone is a principal target for the detrimental actions of glucocorticoid excess in the skeleton (, , -). Some studies reported sex-dependent effects of hypercortisolism on skeletal health, with higher prevalence of osteoporosis at the spine in men compared with women (, ). As in other pituitary diseases (see "Acromegaly" and "PRL-oma" under "Hyperfunctioning pituitary diseases" above and "GHD" under "Hypopituitarism" below), patients with childhood-onset Cushing disease (CD) have lower BMD z scores compared with adult-onset CD (). Some studies showed that adrenal (, ) or ectopic () etiology of hypercortisolism may be associated with higher prevalence of vertebral osteoporosis, perhaps because the higher adrenal androgens in ACTH-dependent hypercortisolism have a protective action on the skeleton. Indeed, this topic is still controversial because other studies did not confirm the difference in skeletal phenotype between ACTHdependent and ACTH-independent hypercortisolism (, ).
Effects of hypercortisolism on risk of fractures and bone structure. Available studies (, -, -) on fracture risk and bone structure in treated and untreated CD are reported in Table  .
The prevalence of fractures has been reported to be % to % (-, -), with the most frequent involving the ribs and vertebrae (, , , -). These rates were likely an underestimation of real fracture risk in CD, because not all patients underwent morphometric and radiological evaluation, and asymptomatic vertebral and rib fractures may remain undiagnosed (, , ). In fact, when searched by a radiological morphometric approach, the prevalence of VFs was found to be % in patients with CD, with half of them being clinically symptomatic associated with pain, functional limitation, and height shortening by  to  cm of final stature (). High prevalence of fractures was reported even in young patients with CD (). Although fragility fractures were generally considered as an early complication of exposure to glucocorticoid excess (, ), the prevalence of clinical fractures in CD correlated with duration of hypercortisolism (). Vestergaard et al. () retrospectively reported a sixfold increase in risk of clinical fractures in the  years before diagnosis of endogenous hypercortisolism (CD in % of cases), without significant differences between CD and adrenal disease. In another retrospective study, the prevalence of VFs and nonvertebral fractures was high since  years before diagnosis of CD (). Patients with bone fractures (including both vertebral and peripheral fractures) compared with patiens without fractures showed increased levels of urinary free cortisol (), and the risk increased .% for every  nmoL urinary free cortisol per -hour increase (), supporting the concept that skeletal fragility is a direct consequence of hypercortisolism. Gonadal status appeared to influence the risk of fractures only in patients with a mild increase in cortisol secretion, whereas in patients with overt CD the potential protective effect of eugonadism was overcome by overt hypercortisolism ().
In some studies, the prevalence of VFs and rib fractures was found to be significantly higher in men compared with women (, ), although such a difference was probably influenced by sex-dependent differences in CD activity.
Despite the effects of glucocorticoid excess on bone quality being well known and characterized (, , ), data on bone microstructure in endogenous hypercortisolism are scant. In a study of  eugonadal women who had endogenous hypercortisolism (CD in .% of the cases), Chiodini et al. () found significant decreases in spinal and forearm trabecular bone mass by quantitative CT, accompanied by decreased spinal and femoral BMD by DXA, whereas forearm cortical bone mass was not decreased. Recent HR-pQCT data suggest also cortical bone resorption as a relevant effect of endogenous hypercortisolism. In fact, using HR-pQCT, dos Santos et al. () reported lower cortical area, thickness, and density in patients with endogenous hypercortisolism (.% with CD) as compared with control subjects, independently of gonadal status.
In summary, patients with CD have a low bone turnover osteoporosis characterized by a severe suppression of bone formation leading to an increased risk of fragility fractures, mainly involving vertebrae and ribs. BMD is generally mildly decreased, but some patients may develop fractures even when bone mass is not apparently low (see "Bone Density and Quality as Predictors of Fractures in Pituitary Diseases" below).
TSH-oma
TSH-oma is a rare disease causing a secondary hyperthyroidism that is usually longer standing and milder as compared with the primary thyroid disease (). Although thyroid hormone excess is a wellknown cause of secondary osteoporosis (), very few studies have investigated the skeletal effects of TSH-oma, with data limited to biochemical markers of bone turnover (, ), whereas data on BMD and fractures were anecdotal (). Bone resorption was shown to increase in patients with TSH-oma with values being comparable to those seen in primary hyperthyroidism and closely correlated to serum thyroid hormone levels (). Consistently, normalization of bone turnover was observed after treatment of TSH-oma (). In a clinical case report, very low BMD values at the lumbar spine and multiple VFs were reported to be the presenting clinical features of TSH-oma (), suggesting that skeletal fragility may be an early complication of secondary hyperthyroidism. Future studies will allow definitive clarification of the true frequency of fragility fractures in patients with TSH-oma.
Hypopituitarism
Hypopituitarism is an uncommon condition with an incidence and prevalence estimated to be . GHD GHD is a frequent pituitary defect with relevant impact on clinical presentation of hypopituitarism (). Severe GHD in adults is associated with adverse changes in body composition, lipid metabolism, insulin sensitivity, and exercise capacity (). Moreover, adult patients with GHD suffer from skeletal fragility, which may potentially contribute to the impaired quality of life and increased risk of mortality observed in patients with hypopituitarism (). Effects of GHD on bone turnover and calcium metabolism. Patients with GHD have a marked reduction in bone turnover, with both formation and resorption being suppressed (-). Moreover, a mild state of skeletal, intestinal, and renal PTH resistance has been described in patients with GHD (, ). GHD also is accompanied by abnormalities in the circadian rhythm of PTH, which may affect bone remodeling (, , ).
Effects of GHD on BMD. Decreased BMD is reported in patients with GHD in relationship to duration, age of onset, and severity of GHD. In childhood-onset GHD, vertebral BMD is markedly reduced, with T scores often between 2 and 2 SD; approximately a third of the patients have T scores of 2. SD or less (). In contrast, patients with adult-onset GHD often have vertebral T scores of 2 SD or higher (, , -). The reason for the different degrees of bone loss may be related to the longer duration of the disease and the defective achievement of peak bone mass in childhood-onset GHD as compared with adult-onset GHD (-). Alternatively, one could argue that lower BMD in childhood-onset disease may be due to an underestimation of BMD related to low size and volume of bones in short patients with GHD (). In fact, a study of life-long untreated childhood-onset GHD showed a reduction in areal BMD (mean z scores -. to -. SD), whereas the calculated volumetric bone density was normal (). However, other studies reported low BMD results even after appropriate correction for height or when quantitative CT was used to measure true volumetric BMD, suggesting that long-standing GHD may cause bone loss regardless of the effects on skeletal growth (, ).
The age of patients with adult-onset GHD influences degree of bone loss and BMD values. In fact, patients , years of age have more severe osteopenia (, , ), whereas BMD of GHD patients . years of age often does not differ from healthy controls (, , ).
The degree of bone loss in adult-onset GHD correlates with severity of the disease (, , , ). Patients with severe GHD, as defined by a GH response , . to . mg/L after GH releasing hormone and arginine (), display significant reductions in BMD (, ).
The underlying disorders leading to GHD may influence the bone phenotype of GHD (, ). The pharmacoepidemiological survey KIMS (Pfizer International Metabolic Study) including  adult GHD patients showed that BMD both at lumbar spine and femoral neck was significantly lower in cases treated for CD ( patients), as compared with those treated for acromegaly ( patients) and other pituitary diseases ( patients), likely reflecting the longterm negative effects of previous hypercortisolism on the skeleton ().
The specific role of GHD in relationship to other pituitary deficiencies in inducing bone loss in hypopituitarism is uncertain. In some studies, patients with isolated GHD had comparable bone loss to that occurring in the presence of multiple pituitary deficiencies (, , , , , ). Alternatively, adult patients with isolated GHD due to mutation of the GHRH receptor were shown to have reduced bone size but normal volumetric BMD of the lumbar spine and hip ().
Effects of GHD on fractures and bone structure. Available studies (, , , , -) on fracture risk and bone structure in treated and untreated GHD are reported in Table  . Abbreviations: Acro-GHD, GHD developing after treatment of acromegaly; AO-GHD, adult-onset GHD; CD-GHD, GHD developing after treatment of CD; CO-GHD, childhood-onset GHD; F, female; HypoA, hypoadrenalism; HypoG, hypogonadism; HypoT, hypothyroidism; L-T4, L-thyroxine; M, male; MAR, mineral apposition rate; pts., patients; ↑, increased; ↓, decreased; ↔, unchanged. a The remaining patients had normal function.
The risk of fractures is twofold to fivefold higher in adult GHD patients as compared with control subjects, regardless of the existence of other pituitary hormone deficiencies (, , , ). Former studies reported an increase in the prevalence of peripheral fractures, pointing to the fragility of cortical bone (, , ). However, these studies were performed by questionnaires or databases that did not capture the true prevalence of VFs in this clinical setting. In , Mazziotti et al. () evaluated for the first time the prevalence of radiological VFs in adult patients with GHD. More than % of these patients were shown to have VFs, which were multiple and/or moderate/ severe in~% and % of the cases, respectively. These were not simple radiological findings, because .% of patients with fractures had one or more signs and symptoms consistent with spinal fractures, in close relationship to the number and severity of fractures. Male and female GHD patients showed comparable prevalence of VFs (), suggesting that skeletal fragility was a general and sex-independent complication of GHD, as demonstrated for acromegaly (, ). Consistent with previous observations, a recent prospective study showed that .% of patients with untreated GHD developed radiological VFs during a period of  years ().
Bone biopsies from male adult patients with GHD reveal decreased osteoid and mineralizing surfaces and decreased bone formation rate (). Surprisingly, a recent study did not find any abnormalities in cortical and trabecular bone microarchitecture and estimated bone strength as assessed by HR-pQCT and microfinite element analysis in adult males with GHD (). Indeed, some of these patients had previously received GH replacement . months before the study, and this may have counteracted any abnormalities in bone structure and strength at the time of evaluation, consistent with the concept that beneficial effects of replacement therapy may be persistent after rhGH withdrawal () (see "Therapeutic options" under "Treatment of hypopituitarism" below).
Other pituitary hormone deficiencies Central hypogonadism can be as frequent as % in patients with sellar tumors and after surgery or radiotherapy; it is also frequent for patients who have had cranial irradiation for nonsellar lesions () and in patients with hyperprolactinemia. Acquired central hypothyroidism occurs in % to % of patients with pituitary diseases and is usually associated with other pituitary hormone deficiencies (-). Almost a third of the hypopituitary patients may have adrenal insufficiency (), with prevalence raising up to % after craniopharyngioma surgery ().
Patients with idiopathic hypogonadotropic hypogonadism have been found to have universally lower BMD compared with age-matched controls, although no data for possible increased fracture risk were available (-). Interestingly, there is some evidence that men with hypogonadotropic hypogonadism had lower baseline BMD as compared with men with primary hypogonadism (, ), inconsistent with the experimental evidence that low FSH values may be protective for bone loss caused by sex steroid deficiency (see "FSH" under "Physiology and Pathophysiology of Pituitary Hormone Action in Bone" above).
Using data extracted from KIMS, Tritos et al. () evaluated the skeletal impact of untreated hypogonadism in  patients with untreated adult-onset GHD. Hypogonadal patients were older and had lower IGF-I values and lumbar spine and femoral neck BMD in comparison with sex steroid-sufficient subjects. In the multivariate analysis, untreated hypogonadism maintained the significant association with BMD at the lumbar spine but not at the femoral neck (). However, hypogonadism did not show a significant influence fracture risk in patients with untreated GHD (, , ). In fact, prevalence of fragility fractures was high in untreated GHD regardless of whether hypogonadism was treated or not (, , ). In other experiences, nontraumatic fractures were more frequent in patients with multiple pituitary hormone deficiencies as compared with those with isolated GHD () ( Table ) .
In the KIMS database, central hypothyroidism and hypoadrenalism were shown to be independently associated with lower lumbar spine BMD ().
In summary, GHD is the most important determinant of skeletal health in hypopituitary patients, causing a low bone turnover osteoporosis with high risk of VFs and nonvertebral fractures. The deterioration of bone quality seems to be the main determinant of fractures in GHD patients, although the studies so far performed have not clarified which are the microstructural skeletal abnormalities underlying skeletal fragility in this clinical setting (, ). Central hypogonadism may influence BMD in hypopituitary patients, but the impact on fracture risk seems to be lower as compared with untreated GHD. Central hypothyroidism and hypoadrenalism per se may cause skeletal fragility, likely reflecting the potential negative effects of low glucocorticoid (see "Key hormonal players" under "Regulation of Bone Metabolism" above) and TSH (see "TSH" under "Physiology and Pathophysiology of Pituitary Hormone Action in Bone" above) values on skeletal remodeling. Of note, patients with isolated hypoadrenalism may develop a functional and transient GHD (Giustina effect) (, , ) that may contribute to causing bone loss in this clinical setting (, ). Moreover, the association between low BMD and central hypoadrenalism or hypothyroidism may reflect the potential negative effects of pituitary hormone overreplacements frequently observed in patients with hypopituitarism (see "Hypopituitarism" under "Effects of Treatment of Pituitary Diseases on Skeletal Endpoints" below).
Bone Density and Quality as Predictors of Fractures in Pituitary Diseases
Fragility fractures are the major clinical consequence of osteoporosis with potential impact on quality of life and survival. Therefore, predicting the absolute risk of osteoporotic fractures is of paramount importance mainly because prevention strategies have to be undertaken. Measurement of BMD by DXA at the lumbar spine, femoral neck, and total hip is used as the primary surrogate of bone strength in the clinical diagnosis of osteoporosis () (see "Clinical Skeletal Endpoints and Diagnostic Tools" above). However, BMD could have limited sensitivity when used alone for prediction of fractures in the general population (), because about half of all fractures occur in women with BMD values above the World Health Organization's diagnostic threshold for osteoporosis (i.e., T score # 2. SD) (, ). This inconsistency derives from the inability of bidimensional DXA measurement to capture the deterioration of bone microstructure and is even more evident in patients with secondary osteoporosis, as those with pituitary diseases (), in whom bone quality is impaired more than bone quantity ().
In a recent meta-analysis (), five studies compared acromegaly patients with and without fractures for lumbar BMD (, , , , ). These studies did not show any difference in BMD between the two groups, although the heterogeneity was too high to achieve conclusions in this regard (). Of note, VFs occurred even in patients with normal BMD, especially when acromegaly was active (), supporting the concept that bone quality is impaired as an effect of GH hypersecretion, and DXA measurement of BMD is of limited reliability in predicting fractures when patients have persisting active disease. However, although VFs may occur regardless of absolute densitometric values, repeated measurements of BMD may provide some information about the ongoing risk of VFs. In fact, in a prospective study, patients experiencing incident VFs were shown to have significant reduction in BMD at femoral neck during follow-up ().
In the other pituitary diseases, the relationship between BMD and fractures was investigated by fewer studies. Patients with fractures with PRL-oma showed lower lumbar spine BMD as compared with patients without fractures (, ), although such an association was lost after adjustment for duration of disease (). As expected by the large experience with exogenous glucocorticoid-induced osteoporosis (), a remarkable number of patients with CD may fracture in the presence of low-normal or even normal BMD values (-, ). Alternatively, when BMD values were in the range of osteoporosis, the prevalence of VFs in CD was shown to be higher (, ), and lumbar spine BMD was shown to be an important predictor of fractures in untreated () and treated CD ().
In hypopituitarism, only two studies evaluated the correlation between fractures and BMD. In patients with untreated GHD, VFs were associated with BMD, because the highest risk to develop fractures was found in patients with a T score below 2. SD (). Of note, all untreated patients with osteoporosis (T score # 2. SD) and all but one patient with osteopenia (T score between 2. and 2. SD) had VFs. However, VFs occurred also in a significant percentage of patients with normal BMD (). When the analysis was performed prospectively, the incidence of VFs was significantly correlated with change in lumbar spine BMD T scores and z scores during the study period ().
Therefore, available evidence in the literature suggests that when DXA measurements of BMD report either a decrease of BMD values or an absolute BMD value in the range of osteoporosis, the risk of fractures is high. Alternatively, the finding of normal or low-normal BMD does not exclude that patients may develop fractures. In these cases, other diagnostic tools are needed to identify patients at high risk of fractures.
During the last decade, several algorithms [e.g., the fracture risk assessment tool] have been proposed to estimate fracture probability in the general population, combining individual risk factors and BMD values (). In patients with pituitary diseases, the experience with these algorithms is limited (, ), with inconclusive results concerning the reliability in predicting fractures in this clinical setting.
The morphometric analysis allows identifying patients with prevalent VFs, which are a marker of skeletal fragility () predisposing patients to develop other fractures (), even when VFs are mild in severity (). This concept has been confirmed even in the specific setting of pituitary diseases by few prospective studies performed in patients with acromegaly (, ) or GHD ().
Patients affected by pituitary diseases, without prevalent VFs and densitometric diagnosis of osteoporosis, may still develop fragility fractures. In these cases, the evaluation of bone microstructure may provide some reliable information on the risk of fractures (see "Pituitary Diseases and Skeletal Endpoints" above). However, only few studies investigated the relationship between fragility fractures and deterioration of bone microstructure (, , , ). All of these studies were cross-sectional, and most of the data were derived from patients with acromegaly in whom VFs were associated with impaired trabecular and cortical microstructure evaluated by either HRpQCT () or bone histomorphometry (). Two studies investigated the association between bone microstructure and fractures in patients with CD (, ). TBS was shown to be deteriorated more than BMD, but both the parameters were not associated with fractures (). Similarly, vertebral and nonvertebral fractures in CD were not associated with trabecular and cortical bone microstructure as measured by HR-pQCT (). These results were likely influenced by the cross-sectional design of studies, because in ACTH-independent hypercortisolism abnormalities of bone microstructure were shown to be predictive of incident VFs ().
Effects of Treatment of Pituitary Diseases on Skeletal Endpoints
Treatment of hyperfunctioning pituitary diseases
Therapeutic options
Neurosurgery. Neurosurgery is the first-line therapy of CD (), acromegaly (, ), and TSH-oma (). When performed by experienced neurosurgeons (), remission of pituitary hyperfunction can be achieved in % to % of patients with microadenomas and % to % of those with macroadenomas, with a % to % of recurrence rate over several years (, ). In PRL-oma the surgical approach can be offered to symptomatic patients who are resistant or cannot tolerate high doses of dopamine agonists (), or even also to micro-PRL-oma patients who prefer/need a rapid resolution of hyperprolactinemia without undergoing long-term dopamine agonist therapy ().
Medical therapies. Dopamine agonists are the first-line therapy of PRL-oma because they may normalize PRL values, decrease tumor mass, and improve clinical symptoms in most patients (, ). Carbergoline was shown to be more effective in normalizing PRL values, with fewer side effects, as compared with bromocriptine ().
First-generation somatostatin receptor ligands (SRLs), octreotide long-acting repeatable (LAR) and lanreotide autogel, are the first-line medical therapy of acromegaly either when surgery fails to control GH/ IGF-I hypersecretion or as first-line therapy in patients with a low probability of surgical cure (, , ). In clinical trials, octreotide LAR and lanreotide autogel have been reported to normalize GH and IGF-I in half to two-thirds of patients (), whereas success rate was shown to be lower in surveys involving nonselected cohorts of patients (). Of note, the biochemical control of acromegaly can be improved by increasing the SRL dose (, ) and frequency () over the conventional regimens. Besides the biochemical control of acromegaly, SRLs can induce tumor shrinkage in .% of treated patients (, ), making these drugs effective as a first-line therapy of acromegaly as an alternative to neurosurgery when contraindicated or not accepted by the patients (). When first-generation SRLs fail to control GH hypersecretion, pegvisomant or pasireotide can be used (-). Pegvisomant is a pegylated recombinant GH analog designed to interfere with dimerization of GHR and thus blocks production of IGF-I () without any direct effect on pituitary tumor. Normalization of IGF-I values occurs in % to % of acromegaly patients treated with pegvisomant (, ). Pegvisomant has been used either alone or in combination with first-generation SRLs or cabergoline to improve the clinical and biochemical control of acromegaly and to prevent the growth of pituitary tumors (, ). Pasireotide LAR is a multireceptortargeted SRL that was shown to normalize GH and IGF-I values in % of patients not responding to first-generation SRLs (). Dopamine agonists may be used in acromegaly patients with mild disease in whom baseline IGF-I values are close to the upper limit of the normal range ().
In CD, nearly a third of patients experience in the long-term a failure of surgery and require an additional second-line treatment (). Medical therapy of CD has recently become more important in comparison with the past owing to the recent availability of drugs able to control cortisol secretion or action, such as pasireotide, mifepristone, and adrenal steroidogenesis inhibitors (-). Pasireotide normalized urinary cortisol values in % to % of patients with CD (, ). Mifepristone is a glucocorticoid receptor antagonist that improves glucose tolerance, body weight, and quality of life in CD (). Monitoring of mifepristone treatment can be difficult because ACTH and cortisol levels increase rather than decrease, and overdosing causing adrenal insufficiency can occur (). Currently available adrenal steroidogenesis inhibitors, including ketoconazole, metyrapone, etomidate, and mitotane, have variable efficacy and significant side effects, but they are not approved by the US Food and Drug Administration for CD ().
Patients with TSH-oma with persistent hyperthyroidism after neurosurgery can be treated with firstgeneration SRLs that can normalize TSH and thyroid hormone levels in .% of patients and reduce tumor size in .% of patients ().
Radiation therapy. Radiation therapy is generally used as a third-line treatment of hyperfunctioning pituitary adenomas, occasionally as a second-line treatment, but rarely as a first-line treatment "It is still unclear whether SRLs and pegvisomant may have direct effects on the skeleton independent of biochemical control of acromegaly."
(, , , ). Traditionally, radiotherapy has been given in a fractionated manner at standard doses, whereas stereotactic radiosurgery is a more modern method that delivers a single dose of irradiation with high conformity and selectivity. The two approaches were shown to have comparable efficacy and safety (), and the choice of the technique is generally dependent on the tumor characteristics. Radiotherapy is preferred for large tumor remnants or tumors that are too close to optic pathways, whereas radiosurgery is preferred for smaller tumors ().
Skeletal endpoints in treated acromegaly
In cross-sectional and prospective studies, biochemical control of acromegaly was associated with a decrease in serum levels of biochemical markers of bone turnover (, , , , , , ). This biochemical effect was accompanied by variable changes in BMD (, , , , , , , ) and with persistently abnormal bone structure (, ). In fact, structural properties of trabecular and cortical bone may be persistently deteriorated after reversal of GH hypersecretion, as suggested by the impairment of TBS during the first months of treatment in eugonadal males with acromegaly () and low bone material strength evaluated by impact microindentation in patients with long-standing controlled acromegaly () ( Table ) .
Duration of active disease is the most important determinant of VFs in acromegaly (), and the fractures are threefold more frequent in patients with persistently active disease as compared with those in whom acromegaly is controlled by the treatment (-, , ). However, some patients with controlled acromegaly still maintained high fracture risk, specifically in the presence of untreated hypogonadism (, ) and diabetes mellitus () ( Table ) . Interestingly, both the clinical conditions did not significantly impact the risk of VFs when acromegaly was active, suggesting that the negative skeletal effects of abnormal glucose metabolism and lack of sex steroids may be overcome by those produced by chronically increased GH and IGF-I levels.
Of note, the risk of VFs persisted high in patients with controlled acromegaly and pre-existing (i.e., prevalent) VFs (, ). This latter finding reflects the so-called domino effect confirming that in acromegaly, such as in other forms of osteoporosis (, ), VFs are always a hallmark of skeletal fragility. This concept is particularly important in acromegaly, where VFs often occur in the presence of normal or even high BMD, leading to a misconsideration of the decrease in vertebral height, as assessed by quantitative morphometry, just as a radiological artifact.
There is evidence that SRLs and pegvisomant may have pleiotropic effects on peripheral targets of acromegaly with potential improvement of clinical endpoints regardless of the achievement of a strict biochemical control of disease (, , ). It is still unclear whether SRLs and pegvisomant may have direct effects on the skeleton independent of biochemical control of acromegaly. In a prospective study, incident VFs were reported to occur more frequently during treatment with pegvisomant as compared with SRLs (). In fact, such a finding may reflect different severity of acromegaly in patients treated with the two drugs. Additionally, the association between pegvisomant and incident VFs was lost after adjustment for activity of acromegaly (). In a recent longitudinal study, the introduction of pegvisomant in the medical therapy of acromegaly (either alone or in combination with SRLs) was accompanied by a significant decrease in the incidence of VFs, in close relationship with biochemical control of acromegaly (). When acromegaly was controlled, no significant difference in incident VFs was observed between pegvisomant and SRLs ().
Skeletal endpoints in treated PRL-oma
In patients with PRL-oma, treatment with dopamine agonists was accompanied by normalization of serum markers of bone turnover in relationship to normalization of PRL values and restoration of gonadal function (, ). BMD values, however, only partially improved during treatment, remaining still lower as compared with normal control subjects (, -, , -). In general, the improvement of BMD was associated with the recovery from hypogonadism, more than to the suppression of PRL levels (-, , , , ).
The effects of dopamine agonists on fracture risk are largely unknown, because only three crosssectional studies have investigated the prevalence of fractures in relationship to treatment of PRL-oma (, , ) ( Table ) . Vestergaard et al. () showed a % decrease of annual rate of clinical fractures after diagnosis of PRL-oma, suggesting a positive impact of treatment on fracture risk. Combining the studies that evaluated radiological VFs, treatment with dopamine agonist was accompanied by a significant decrease in fracture risk (OR, .; % CI, . to .) (). However, whether the treatment of PRL-oma may normalize the fracture risk is still unclear. In fact, male patients under treatment of PRL-oma showed still higher prevalence of VFs as compared with age-matched control subjects ().
Skeletal endpoints in treated CD
Correction of hypercortisolism was accompanied by a marked increase in osteocalcin levels and moderate increase or even decrease in NTX levels (, ). These changes in bone turnover are expected to be associated with an increase in BMD, although the densitometric outcomes after treatment of hypercortisolism were shown to be variable, with some patients recovering normal BMD (, ) and others showing persistently abnormal BMD for several years after the cure of CD (, -). Differences in duration of follow-up (, , ), uncertainties in the definition of the cure of hypercortisolism (), and potential confounding effects of hormone pituitary deficiencies developing after surgical treatment of CD () may partially explain the variable outcome of BMD reported in different studies, whereas the potential impact of different therapies of CD on skeletal endpoints is still a matter of uncertainty. Changes in BMD after the cure of CD are time-dependent and skeletal site specific. The increase in BMD was larger and occurred earlier at the lumbar spine as compared with the total hip (, ). Interestingly, BMD decreased at the distal and total radius in the first  to  years after the cure of hypercortisolism, and this finding was explained by a possible redistribution of bone minerals from the peripheral to axial skeleton (). The recovery of BMD after the cure of CD seems to occur earlier in children as compared with adults, likely reflecting both the rapid growth and the increase of bone turnover in the first decades of life (, ). However, persistently pathological BMD was reported in children several years after cure of CD (, ). Based on these data, a close densitometric monitoring is required in all (adults and children) treated CD patients, even in those achieving biochemical remission of disease.
Interestingly, improvement in lumbar spine BMD after the cure of hypercortisolism was predicted by a decrease in body mass index during the follow-up period (), suggesting a role for fat tissue in the pathophysiology of bone recovery after remission of CD ().
The close association between fragility fractures and severity of hypercortisolism () and duration of disease () suggests that an early treatment of CD may have a favorable impact on fracture risk (). In fact, Vestergaard et al. () reported a significant decrease in risk of clinical fractures early after diagnosis of CD (Table ) , although it was not specified whether this outcome was related to correction of hypercortisolism or to other treatments (e.g., sex steroids or vitamin D) potentially impacting fracture risk in this clinical setting (-). In a retrospective analysis, no incident clinical fractures were registered during a period of  years after the cure of hypercortisolism, although the number of patients with long-term follow-up was too low to draw definitive conclusions (). Alternatively, a high prevalence of VFs was reported in patients with long-standing cured CD (Table ) , although the cross-sectional design did not allow definition of the timing of fracture development and progression in relationship to the outcome of hypercortisolism (). Of note, patients with previous fractures were predisposed to develop new fractures after treatment of CD (), confirming that fractures are a hallmark of skeletal fragility in CD such as observed in other pituitary diseases (, ).
In summary, the biochemical control of acromegaly, PRL-oma, and CD was shown to be associated with a significant decrease in the risk of fractures, especially when an effective treatment was undertaken early after diagnosis of disease. However, some patients with cured pituitary disease may maintain high risk of fractures, providing the rationale to use boneactive drugs in this specific clinical setting (see "Treatment With Bone-Active Agents in Pituitary Diseases" below).
Treatment of hypopituitarism
Therapeutic options
The aim of hormone replacement is to safely eliminate or minimize the symptoms and clinical signs of specific hormone deficiencies. With the exception of rhGH and treatment of infertility, replacement therapy consists of the administration of target hormones. Hypoadrenalism is the first deficiency that must be replaced either to prevent adrenal crisis after starting treatment with thyroid hormones or to better evaluate the pituitary axes that may by influenced by glucocorticoids, such as the GH/IGF-I axis (Giustina effect) (, , ). There is a significant heterogeneity in the type, dose, frequency, and timing of glucocorticoid replacement of adrenal insufficiency in real-life clinical practice (). This is increased by the absence of reliable biochemical or clinical markers of adequacy of glucocorticoid replacement. The guidelines indicate to use hydrocortisone at  to  mg daily, whereas longer acting glucocorticoids can be used in some selected cases, such as nonavailability of hydrocortisone and poor compliance (). Hydrocortisone has a short half-life (~ minutes) (), and multiple dosing is recommended to try mimicking physiological conditions. When long-acting glucocorticoids are used, one daily dose of~ mg of prednisone and . mg of dexamethasone is sufficient to replace cortisol insufficiency (, ). However, even when used at equivalent physiological doses, prednisone and dexamethasone may potentially cause unfavorable effects due to their long half-life not resembling the physiological daily rhythm of cortisol (). Patients with hypopituitarism under treatment with rhGH and estrogens may need higher glucocorticoid dose as compared with patients in whom GHD and hypogonadism are not replaced, owing to the inhibitory effects of GH on peripheral activation of cortisone in cortisol () and the decrease of cortisol bioavailability induced by estrogens ().
Central hypothyroidism is replaced with L-T in doses sufficient to achieve serum FT levels in the "The effect of rhGH on bone remodeling is biphasic." middle to upper half of the reference range, whereas TSH cannot be used to choose the appropriate L-T replacement dose. L-T doses in central hypothyroidism average . mg/kg/d, based on the evidence that this hormone dose was associated with an improvement in several clinical endpoints of central hypothyroidism (-). However at these doses, L-T may cause skeletal fragility, especially when GHD is replaced (see "Treated hypothyroidism" under "Hypopituitarism" below).
rhGH is offered to adult patients with biochemically proven GHD to improve body composition, exercise capacity, quality of life, cardiovascular outcomes, and skeletal fragility (, ). Treatment is started with low doses of rhGH (i.e., .-. mg/d), which are then uptitrated to maintain serum IGF-I in the normal range for age ().
Sex hormones are given in place of gonadotropins to patients with central hypogonadism when fertility is not an endpoint.
Skeletal endpoints in treated GHD
Effects of rhGH on bone turnover and calcium metabolism. Replacement therapy with rhGH leads to an increase in bone turnover, as determined by changes in biochemical markers of bone resorption and bone formation (). The effect of rhGH on bone remodeling is biphasic; that is, rhGH causes a maximal effect on bone resorption after  months and on bone formation after  months. The effect on bone formation is sustained for prolonged periods of time (, , -). The effect of rhGH on biochemical markers of bone turnover is dosedependent (, , , ) but not influenced by the modality of administration (i.e., continuous vs daily administration, and daily vs administration three times a week) (, ). rhGH causes an increase in serum and urinary calcium after  to  months, an effect caused by calcium mobilization from the skeleton, an increase in intestinal calcium absorption, and in the renal reabsorption of calcium due to increased sensitivity to PTH (-). rhGH is antiphosphaturic and increases the intestinal absorption of phosphate, leading to an increase in serum phosphate levels (-). rhGH may normalize the circadian rhythm of PTH secretion ().
The early actions of rhGH on skeletal tissue induce activation of multiple bone remodeling units with consequent expansion of remodeling space and transient removal of bone during resorption before new bone is formed (, ). Interestingly, a recent study reported an increase in circulating and cortical bone matrix protein levels of the Wnt signaling antagonist DKK- in response to  to  months of treatment with rhGH, consistent with the concept that bone formation is blunted during the first months of treatment ().
Effects of rhGH on BMD. The early effects of rhGH on bone turnover may explain why randomized placebo controlled trials of less than a year in duration showed either no significant change in BMD or some decline (, , , , , , -). Randomized placebo-controlled trials of  to  months showed mixed results with either improvements or no effects on lumbar spine BMD (, ). Longer prospective and nonrandomized studies reported more favorable effects of rhGH therapy on BMD (, , ). In a recent meta-analysis including  studies with  patients ( treated for . months), Barake et al. () found a significant increase in lumbar spine and femoral neck BMD when treatment was . months ( to  months). In prospective and retrospective studies of  to  years in duration, lumbar spine BMD continued to increase for up to  years but subsequently plateaued (, , ), whereas femoral neck BMD peaked at  to  years and returned to baseline at  to  years (, ).
Of note, BMD may continue to increase even  months after rhGH discontinuation in contrast to the effects on body composition, which were lost after the discontinuation of rhGH (, ). The mechanisms underlying this effect are largely unknown. It was postulated that GH triggers bone remodeling but may not be required for continued bone gain. Moreover, a prospective study by Appelman-Dijkstra et al. () reported a small decrease in femoral neck BMD at  years after discontinuation of GH in patients , years of age.
Besides the duration of treatment, the variable densitometric response to rhGH may be dependent on other factors, such as the timing of starting rhGH therapy after the diagnosis of GHD, the underlying disease causing GHD, age of patients, baseline skeletal condition, sex of patients, and hormone replacement dose ().
In adult patients with childhood-onset GHD, a longer delay in rhGH replacement during the transition period was negatively associated with bone mineralization at the femoral neck (). This finding is consistent with a relevant role of GH during bone mineral accrual in young adulthood () and suggests that interruptions in rhGH replacement during adulthood may be detrimental to bone health. Interestingly, a greater improvement in lumbar spine BMD was associated with older age at the onset of pituitary diseases ().
Johannsson et al. () in  found that patients with a BMD z score of less than - SD responded significantly better compared with those with a z score greater than - SD (~% vs~%) at all measured sites, but in a meta-analysis of long-term prospective studies, this association was found only in the femoral neck ().
Some studies reported that a high dose of rhGH may cause more significant initial decline in BMD and that a physiologic dose is enough to produce a beneficial effect on BMD (, ). However, the optimal dose to maximize BMD gain is unknown, and a metaanalysis found no correlation between the dose of rhGH and BMD change ().
Interestingly, men responded better than women in both randomized controlled and prospective studies (, , , ), even when the effect was normalized for the dose of rhGH (, , ). These sex-dependent differences may be related to earlier changes in bone remodeling in men as compared with women () and they may also reflect the different impact of hypogonadism in male and female subjects with GHD (, ).
Various pituitary disorders may lead to GHD, of which pituitary adenomas and their treatments are the most common in adults (). The underlying pituitary disease may alter the effects of rhGH on bone mass. Patients with a history of CD, as well as those with hyperprolactinemia and hypogonadism, showed a delayed effect of rhGH replacement therapy on BMD ().
Effects of rhGH on fractures and bone structure. Unlike studies investigating the densitometric endpoints in treated GHD (), no randomized controlled clinical trials are available to evaluate the effects of rhGH on fracture risk in patients with GHD. Cross-sectional studies have suggested that rhGH treatment reduces the risk of vertebral and nonvertebral fractures in GHD in close relationship to the lag time between the diagnosis of GHD and the initiation of therapy () ( Table ) . Indeed, rhGH was beneficial mainly in patients receiving replacement therapy shortly after the diagnosis of GHD was made ().
Underlying genetic differences may play a role in fracture risk of GHD patients. A recent study showed that GHD adults carrying the d-GHR isoform had fewer VFs than did the full-length GHR carriers, despite no difference in BMD. The authors hypothesized that GHR polymorphism may render better bone quality as an effect of higher sensitivity to GH ().
The effects of rhGH therapy on fractures have been evaluated in nonrandomized longitudinal/prospective studies (, , , , ) ( Table ) . In a Swedish cohort of GHD patients treated with rhGH replacement therapy for up to  years, only two clinical fractures were reported (), suggesting an overall protective effects of rhGH therapy on fracture risk. Holmer et al. () retrospectively evaluated the incidence of osteoporotic and nonosteoporotic clinical fractures in  patients with GHD under long-term treatment with rhGH as compared with  matched population controls. The study design limited the possibility of separately evaluating the effects of untreated and treated GHD on fracture incidence, because the person-years risk before starting rhGH therapy was too low for a reliable interpretation of GHD-specific fracture risk. However, this study showed that risk of clinical fractures remained significantly high in treated women with childhood-onset GHD, whereas no risk increase during rhGH therapy was observed among childhood-onset GHD men and adult-onset GHD women () ( Table ) . Interestingly, a significantly decreased incidence of fractures was reported in adult-onset GHD men (). These findings likely reflected the interaction between estrogen insufficiency, oral estrogen and the GH/IGF-I axis during the transition period in childhood-onset GHD women and between testosterone treatment and bone health in adult-onset GHD men, although the potential impact of testosterone therapy on fracture risk in hypogonadal patients is still unclear.
In the postmarketing multicenter Hypopituitary Control and Complication Study, involving  patients followed up for . years, Mo et al. () reported a % decrease in the incidence of clinical fractures during rhGH therapy as compared with untreated patients with GHD (Table ) . However, both treated and untreated patients with osteoporosis had similar fracture rates, suggesting that rhGH may not have the same protective action in more severe cases of bone loss (). This hypothesis was in disagreement with previous studies reporting a better densitometric response to rhGH in patients with lower baseline BMD (). However, details on BMD measurement were lacking in the study of Mo et al. (), and very few patients (% to %) were labeled as osteoporotic. Therefore, debate on the predictive role of BMD on fracture incidence as well as on rhGH protection remains wide open ().
van Varsseveld et al. () evaluated the incidence of clinical fractures in  patients with severe GHD included in the Dutch National Registry of Growth Hormone Treatment in Adults (Table ) . At the baseline and in the first years of follow-up, fracture risk did not differ between patients with previous nonfunctioning pituitary adenomas, CD, and acromegaly, whereas after  years, fracture risk was increased specifically in patients with previous acromegaly () ( Table ) . This finding suggests that rhGH replacement therapy may not fully restore bone health in GHD patients previously exposed to GH excess, especially when treatment of GHD is started late after diagnosis of disease and patients had already developed fractures before replacement therapy.
Only one study prospectively evaluated the effects of rhGH replacement therapy on the risk of radiological VFs () ( Table ) . After  years of follow-up, risk of VFs was sevenfold higher in untreated as compared with treated GHD. Such a difference remained significant even after correction for the age of patients (i.e., untreated GHD patients were older "After 6 years of follow-up, risk of VFs was sevenfold higher in untreated as compared with treated GHD." than the treated ones). Interestingly, the difference in fracture risk between treated and untreated GHD became significant early during replacement therapy, providing the first evidence that the beneficial effects of rhGH on bone quality and skeletal strength may anticipate the improvement of BMD, as assessed by DXA (). This concept is also consistent with the results of rhGH therapy in adults with age-related bone loss and without hypopituitarism. In fact, a recent meta-analysis showed that rhGH could not improve BMD in women with age-related bone loss but was able to decrease fracture risk ().
Changes in TBS in response to rhGH treatment have also been investigated with controversial results. In a prospective uncontrolled study, Kuzma et al. () showed a small but significant increase in TBS after  months of treatment of GHD adults (Table ) . Alternatively, a more recent study failed to demonstrate improvement in TBS after  years of GH substitution () ( Table ) . However, in this study baseline TBS was normal. One could argue that these findings could be explained by smaller GH influence on trabecular bone than on cortical bone. This hypothesis is supported by histomorphometric findings demonstrating an increase in periosteal bone formation during rhGH treatment (), but it is inconsistent with the evidence that rhGH has favorable effects in reducing the risk of VFs ().
Skeletal endpoints in treated central hypogonadism
Replacement treatment with testosterone is recommended to improve skeletal health (). Indeed, treatment increased BMD (, , ) and improved trabecular structure () and bone mechanical properties (), whereas the impact of testosterone therapy on fracture risk is still unknown. In a cross-sectional study performed in  hypopituitary patients ( with preserved gonadal function,  with hypogonadism in adequate replacement therapy with testosterone or estrogens, and  with untreated hypogonadism) a high prevalence of VFs was associated with untreated GHD and was not influenced by treatment of hypogonadism () ( Table ) Table ) .
Skeletal endpoints in treated central hypothyroidism
As opposed to what happens in primary hypothyroidism, TSH cannot be used to monitor replacement therapy of central hypothyroidism and to determine the adequacy of L-T doses (). Therefore, overtreatment of central hypothyroidism may easily occur, especially when other pituitary hormone deficiencies coexist (). For instance, GH status is a major determinant of thyroid hormone biological effects by stimulating the deiodination of T in active T (, ). In a recent post hoc analysis of a study in GHD patients, Mazziotti et al. () reported high prevalence of radiological VFs in patients receiving L-T doses .. mg/kg/d (Table ) . Such an association was more significant in patients with treated GHD, consistent with the physiological concept that peripheral activation of T in T is stimulated by rhGH and treatment of GHD may favor higher exposure of peripheral tissues to thyroid hormones, whereas patients with untreated GHD may be relatively protected by thyroid hormone overtreatment.
Skeletal endpoints in treated central hypoadrenalism
Similarly to central hypothyroidism, an overtreatment of central hypoadrenalism is frequent because replacement therapy does not completely mirror the endogenous hormonal production and its monitoring is also made difficult by the lack of good biomarkers of hormonal actions ().
Some studies investigated the effects of glucocorticoid replacement therapy on BMD. Lower BMD at the lumbar spine and femoral neck was reported in women, but not in men, with treated central hypoadrenalism as compared with hypopituitary subjects with a normal ACTH/adrenal axis (). When the analysis was replicated in patients undergoing replacement therapy of GHD, BMD was shown to improve as an effect of rhGH therapy both in glucocorticoid-sufficient and in glucocorticoidinsufficient patients receiving a mean hydrocortisone dose of  mg/d (). Peacey et al. () studied six patients with central hypoadrenalism in whom the decrease of hydrocortisone dose from  to  mg per day led to mixed results, with some patients improving their BMD and other continuing to lose bone. More recently, Frara et al. () provided the first evidence that the shift of the treatment from conventional hydrocortisone to dual-release hydrocortisone at equivalent doses induced a significant improvement in lumbar spine BMD.
Data on fractures in central hypoadrenalism are scant ( Table ) . Two large studies from the KIMS database showed that glucocorticoid replacement therapy was not associated with an increased risk of clinical fractures, but these studies did not provide information about the glucocorticoid doses used by the patients (, ). In a post hoc analysis performed in  adult males with central hypoadrenalism, the use of hydrocortisone doses . mg/d was associated with higher prevalence of radiological VFs, mainly when GHD was not replaced (), consistent with the physiological concept that in the absence of GH, glucocorticoids are overactivated at the peripheral tissue level () ( Table ) .
Bone-active agents used to treat osteoporosis are classified as antiresorptive and anabolic drugs (). Bisphosphonates inhibit bone resorption and are the most commonly prescribed drugs for the treatment of osteoporosis. Bisphosphonates are approved for treatment of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. Moreover, bisphosphonates were shown to be effective in other forms of secondary osteoporosis, such as in patients with HIV infection and those exposed to estrogen and androgen-deprivation therapies (). Denosumab is a human monoclonal antibody (IgG immunoglobulin isotype) binding RANKL with high affinity and specificity and inducing a reversible inhibition of osteoclastogenesis and bone resorption (). Denosumab is approved for treatment of postmenopausal osteoporosis (), male osteoporosis (), and bone loss in patients with prostate () or breast cancer () undergoing hormone ablation therapy. Denosumab was recently approved also for glucocorticoid-induced osteoporosis. Selective estrogen receptor modulators, such as raloxifene and bazedoxifene, are antiresorptive drugs approved for treatment of postmenopausal osteoporosis (, ). Teriparatide is the - active fragment of PTH with stimulating effects on osteoblastogenesis and bone formation when intermittently administered once daily (). Teriparatide is currently the only anabolic drug approved for treatment of osteoporosis at high risk of fractures () and for glucocorticoid-induced osteoporosis ().
Although treatment of pituitary hormones excess or defect generally improves skeletal health, some patients with cured pituitary diseases as with persistently active diseases may still have high fracture risk, providing the rationale to use bone-active drugs in this specific clinical setting [Table  (-)]. Despite the growing body of knowledge about bone fragility in acromegaly, no studies have been performed so far to test the efficacy and safety of antiosteoporotic drugs in this clinical setting. Therefore, no evidence-based indications can be given in this regard. Nevertheless, use of inhibitors of osteoclastogenesis and bone resorption (i.e., bisphosphonates and denosumab) may have a rationale in patients with active acromegaly to counteract the overstimulating effects of GH and IGF-I excess on bone remodeling (Table ) , particularly in the presence of reduced BMD, a finding that is not so frequent in patients with acromegaly. In this specific setting, the use of estrogens and selective estrogen receptor modulators (e.g., raloxifene) may have a rationale based on their concomitant inhibitory effects on IGF-I production () and bone resorption (). When a progression of skeletal fragility and VFs occurs in patients with controlled acromegaly (, ), an anabolic option may be perhaps considered to restore the impairment of bone quality reported in patients treated for acromegaly (, ).
The only few studies investigating the efficacy of bone-active agents in pituitary diseases were performed in patients with CD and GHD ( Table ) . Di Table ) . Treatment with alendronate (in combination with ketoconazole) induced a significant increase in serum osteocalcin and decrease in serum NTX values, accompanied by a significant increase of lumbar spine and femoral neck BMD. These results may support the use of antiresorptive drugs in patients with persistently active CD, whereas it is uncertain whether this approach could be useful when CD patients are cured (). In fact, it should be considered that bisphosphonates may potentially delay the recovery of bone remodeling after resolution of endogenous hypercortisolism. In this context, teriparatide with its stimulating effects on bone turnover may be an interesting therapeutic option, as suggested by anecdotal data showing favorable effects of this drug on BMD and TBS after cure of CD (, ). Four studies evaluated the efficacy of alendronate in hypopituitary patients with GHD ( Table ) . Valk et al. () evaluated the effects of pamidronate in preventing the increase in bone resorption induced by rhGH in the first months of replacement therapy. The bisphosphonate, administered up-front in six GHD patients treated with rhGH, attenuated the increase in bone turnover and prevented the decline in BMD eventually observed in the first months of GH substitutution. In fact, lumbar spine bone mineral content increased by % after  months of treatment with rhGH and pamidronate (). Biermasz et al. () evaluated the effects of alendronate combined to rhGH after  years of stable replacement therapy in  GHD patients with osteoporosis. During -month treatment, alendronate induced a significant decrease in serum bone markers of bone turnover values, with a more pronounced reduction in NTX vs osteocalcin and ALP (). Interestingly, after  monts of followup lumbar spine BMD increased by .% during rhGH plus alendronate therapy as compared with a decrease of .% in patients treated with rhGH alone (). No changes in femoral neck BMD were observed within the study period in either group, possibly due to the short-term follow-up. Of note, the improvement in lumbar spine BMD correlated with a decrease in markers of bone turnover (), as repeatedly shown with the use of bisphosphonates in the setting of primary osteoporosis (). The same group evaluated the long-term effects of adding alendronate in patients receiving stable rhGH replacement therapy (). After  years of combined treatment of rhGH plus alendronate, BMD increased by .% and .% at the lumbar spine and femoral neck, and these changes were statistically significant as compared with those occurring in patients treated with rhGH alone (). The beneficial effects of alendronate on BMD were accompanied by a decrease in VF incidence, although the study was not powered for this endpoint. In fact, five osteoporotic GHD patients had a total of  VFs before starting alendronate, whereas only one of these patients developed two new VFs within the first year of treatment with alendronate (). More recently, White et al. () evaluated the effects of alendronate in combination with rhGH on PTH sensitivity, bone turnover, and BMD in  GHD patients ( naive and  under chronic replacement therapy). Alendronate attenuated the rhGH-mediated improvement in renal PTH sensitivity and the increase in renal phosphate reabsorption, which occurred later as compared with patients treated with rhGH alone (). Consistent with the results of the previous study (), alendronate induced a significant decrease in bone resorption when given up-front to naive GHD patients, which combined with the increase in osteocalcin may explain the greater increase in BMD observed in the rhGH plus alendronate group as compared with rhGH therapy alone ().
These findings suggest that antiresorptive agents, specifically alendronate, may be used to prevent bone loss during the first months of rhGH therapy in GHD patients. Based on these data, it can be hypothesized also that there is a possible effectiveness of bisphosphonates in active acromegaly (see above). Moreover, there is also evidence that the long-term use of rhGH does not preclude a beneficial effect of antiresorptive agents in GHD patients with osteoporosis. A question that remains unsolved is whether bisphosphonate treatment alone is able to increase BMD in a non-rhGH-substituted GHD patient with a low bone turnover state. Nevertheless, one could probably expect favorable clinical results also in these patients as shown in other low bone turnover states associated with corticosteroid use as well as in elderly patients with postmenopausal osteoporosis in whom bisphosphonates have been shown to be effective in increasing BMD and decreasing fracture risk ().
Future Directions and Conclusions
Pituitary diseases are burdened by relevant osteometabolic derangements. Assessment of bone status should be consistently part of the diagnostic and follow-up approach to such diseases. To this end, a bone expert should be involved in the management of skeletal complications of pituitary patients because the best mix of diagnostic tools must be chosen based on the specific underlying diseases. Because in most cases the densitometric evaluation by DXA is not informative enough concerning the fracture risk (), the morphometric vertebral evaluation currently represents the mainstay of the skeletal investigation in patients with pituitary diseases. Advantages of this approach are represented by its cost-effectiveness, convenience for the patients, ability to target the type of bone most precociously and severely involved (trabecular bone), and to disclose not a theoretical but an actualized risk of fracture. The main drawback of this approach is the relatively delayed information concerning the severity of bone involvement. Therefore, the morphometric vertebral evaluation is likely to remain the method of choice for assessing the bone status in patients under long-term follow up, that is, those at presumably higher risk of already bearing a clinical event. In fact, those patients not fractured after many years of disease can be thought to be in some ways protected from a relevant skeletal involvement. Alternatively, this approach is probably not the best to predict the risk of fracture in patients at diagnosis, that is, those with a presumably low disease load. In these latter patients, the densitometric and morphometric evaluation by DXA should be probably more effectively accompanied by methods evaluating the quality of bone, such as TBS, to allow a better prediction of patient candidates to develop a severe bone complication and also to plan a targeted and more informative skeletal follow-up. Because no specific guidelines have been so far published on this topic, the monitoring of skeletal health in pituitary diseases cannot be evidence based. However, based on our experience achieved in other forms of secondary osteoporosis, such as exogenous glucocorticoid-induced osteoporosis (), hormone-deprivation therapy (), and primary hyperparathyroidism (), one could suggest to perform a regular fracture risk reassessment every  to  months (according to baseline severity of bone disease) by measurement of BMD and, if available, TBS by DXA. In patients with preexisting VFs, regular vertebral morphometric evaluation should be indicated, because independently of the disease status, this represents the condition at the highest risk of subsequent fracture. In patients without VFs at the beginning of follow-up, vertebral morphometry should be re-evaluated when disease is not controlled and only in cases of decreased BMD, when the disease is biochemically controlled. Clinical manifestations (e.g., exacerbation of back pain) may trigger re-evaluation of bone status (with DXA BMD and morphometric evaluation) at any stage of the pituitary disease independently of the control of the disease. Therefore, in the future Pituitary Center of Excellence (), a bone clinic with adequate variety of bone investigation tools should be available to help the pituitary expert in the management of this epidemiologically and clinically high-impact complication.
Research concerning pituitary diseases and bone is very active, and many open issues on both pathophysiological and clinical aspects are in the agenda waiting to be solved. Pathophysiologically, the reciprocal role of pituitary and peripheral hormones in the pathogenesis of bone damage remains to be fully clarified, and the study of human models in which their role can be consistently separated is particularly relevant. Moreover, the cellular and molecular mechanisms through which high GH and IGF-I may cause bone damage in humans still remain to be clarified (). Clinically, the fracture predictive role of methods assessing bone quality and microstructure in vivo needs to be fully elucidated. In fact, although HRpQCT is apparently the gold standard in the arena, its costs make its availability for routine evaluation unrealistic. Other more cost-effective and easy applicable methods, such as TBS (, ), CT cone-beam (), and microidentation (this latter being microinvasive) (), have been proposed in small single-center studies exclusively in acromegaly patients, but their widespread application particularly in routine clinical practice still needs to be validated by large pituitary patient population studies.
Another so far almost unexplored territory is the role of bone-active drugs in the treatment of bone complications in pituitary diseases. This topic is particularly relevant in fractured hyperpituitary patients (particularly in acromegaly and in CD) in whom the cure of underlying disease is often difficult to achieve (, ). In this clinical setting, an opposite approach would be preferred with anabolic treatment in CD () and antiresorptive treatment in acromegaly () unless pathogenetic treatments [i.e., with bone-active molecules specifically affected by the underlying diseases (, , )] will be available in the future.
Another aspect to be discussed is the replacement therapy in patients with GHD. For mainly economic reasons the substitution with rhGH has become progressively less popular in our health systems and among endocrinologists. However, the burden of fractures in hypopituitarism is high and aggravated by concomitant possible overtreatment of cortisol () and thyroid hormone deficiencies (). To prevent or treat bone loss in the GHD patients who are decided not to be treated with rhGH is a clear unmet clinical need and cannot be simply overlooked by us as clinicians in our clinical practice. An intriguing pharmaco-economic topic of discussion could be whether bone anabolic treatments-that is, teriparatide-may be more cost-effective in GHD than its pathophysiological treatment with rhGH. Ad hoc clinical trials to test the efficacy of fracture preventive strategies in pituitary diseases are recommended. Even considering the relative rarity of pituitary diseases, the high incidence of bone-related events makes such studies possible in those populations, despite the need for multicenter trials with long follow-up.
